,terms,label,prediction,extended_terms,extended_prediction
0,p value,arms;measures,measures,p value,measures
1,"p value """,arms;measures,measures,"p value """,measures
2,gemfibrozil,arms;measures,characteristic_name,gemfibrozil,characteristic_name
3,placebo,arms;measures,arms,placebo,arms
4,risk reduction ( nmbr % cl ),arms;measures,measures,risk reduction ( nmbr % cl ),measures
5,p *,arms;measures,characteristic_name,p *,characteristic_name
6,"balloon angioplasty plus abciximab """,arms;measures,arms,"balloon angioplasty plus abciximab """,arms
7,balloon angioplasty plus abciximab,arms;measures,arms,balloon angioplasty plus abciximab,arms
8,stent plus placebo,arms;measures,arms,stent plus placebo,arms
9,pt,arms;measures,measures,pt,measures
10,stent plus abciximab,arms;measures,arms,stent plus abciximab,arms
11,irofiban,measures;arms,characteristic_name,irofiban,characteristic_name
12,no . of patients,measures;arms,characteristic_level,no . of patients,characteristic_level
13,"abciximab """,measures;arms,arms,"abciximab """,arms
14,abciximab,measures;arms,arms,abciximab,arms
15,clopidogrel ( n = nmbr ),arms;measures,arms,clopidogrel ( n = nmbr ),arms
16,"ticlopidine ( n = nmbr ) """,arms;measures,characteristic_level,"ticlopidine ( n = nmbr ) """,characteristic_level
17,p,arms;measures,characteristic_name,p,characteristic_name
18,ticlopidine ( n = nmbr ),arms;measures,characteristic_level,ticlopidine ( n = nmbr ),characteristic_level
19,placebo group ( n = nmbr ),arms;measures,arms,placebo group ( n = nmbr ),arms
21,warfarin group ( n = nmbr ),arms;measures,arms,warfarin group ( n = nmbr ),arms
22,"warfarin group ( n = nmbr ) """,arms;measures,arms,"warfarin group ( n = nmbr ) """,arms
23,placebo group,arms;measures;p-interaction,arms,placebo group,arms
24,"placebo group """,arms;measures;p-interaction,arms,"placebo group """,arms
25,p value for interaction^,arms;measures;p-interaction,measures,p value for interaction^,measures
26,hazard ratio ( nmbr % ci ) *,arms;measures;p-interaction,measures,hazard ratio ( nmbr % ci ) *,measures
27,warfarin group,arms;measures;p-interaction,arms,warfarin group,arms
28,rr ( nmbr % cl ),arms;measures,measures,rr ( nmbr % cl ),measures
29,non - calcium antagonist strategy ( ncas ) ( events / n ),arms;measures,arms,non - calcium antagonist strategy ( ncas ) ( events / n ),arms
30,"non - calcium antagonist strategy ( ncas ) ( events / n ) """,arms;measures,arms,"non - calcium antagonist strategy ( ncas ) ( events / n ) """,arms
31,calcium antagonist strategy ( cas ) ( events / n ),arms;measures,arms,calcium antagonist strategy ( cas ) ( events / n ),arms
32,esrd on placebo ( % ),measures;arms,arms,esrd on placebo ( % ),arms
33,chf on placebo ( % ),measures;arms,arms,chf on placebo ( % ),arms
35,esrd on losartan ( % ),measures;arms,outcomes,esrd on losartan ( % ),outcomes
36,chf on losartan ( % ),measures;arms,arms,chf on losartan ( % ),arms
37,p ( losartan versus placebo ),measures;arms,arms,p ( losartan versus placebo ),arms
38,"p ( losartan versus placebo ) """,measures;arms,arms,"p ( losartan versus placebo ) """,arms
39,gfr ( ml / min per nmbr . nmbr nr ),measures;arms,characteristic_level,gfr ( ml / min per nmbr . nmbr nr ),characteristic_level
40,risk reduction ( % ; nmbr % ci ),measures;arms,measures,risk reduction ( % ; nmbr % ci ),measures
41,"placebo ( n = nmbr , nmbr )",arms;measures,arms,"placebo ( n = nmbr , nmbr )",arms
42,"nmbr % ci """,arms;measures,measures,"nmbr % ci """,measures
43,nmbr % ci,arms;measures,measures,nmbr % ci,measures
44,rr *,arms;measures,characteristic_name,rr *,characteristic_name
45,"beta - carotene ( n = nmbr , nmbr )",arms;measures,characteristic_level,"beta - carotene ( n = nmbr , nmbr )",characteristic_level
51,beta - carotene,arms;measures,arms,beta - carotene,arms
56,p interaction,arms;measures,characteristic_name,p interaction,characteristic_name
58,asp,arms;measures,characteristic_name,asp,characteristic_name
60,rr ( nmbr % ci ),arms;measures,measures,rr ( nmbr % ci ),measures
61,pla,arms;measures,arms,pla,arms
62,"patients with end point """,arms;measures,characteristic_level,"patients with end point """,characteristic_level
63,patients with end point,arms;measures,characteristic_level,patients with end point,characteristic_level
64,"p - value * ' ' """,arms;p-interaction,measures,"p - value * ' ' """,measures
65,eze nmbr mg,arms;p-interaction,arms,eze nmbr mg,arms
66,pbo,arms;p-interaction,arms,pbo,arms
67,p - value * ' ',arms;p-interaction,measures,p - value * ' ',measures
68,p value,arms;p-interaction,measures,p value,measures
69,aspirin ( n = nmbr nmbr ),arms;p-interaction,characteristic_level,aspirin ( n = nmbr nmbr ),characteristic_level
70,placebo ( n = nmbr nmbr ),arms;p-interaction,arms,placebo ( n = nmbr nmbr ),arms
71,"placebo ( n = nmbr nmbr ) """,arms;p-interaction,arms,"placebo ( n = nmbr nmbr ) """,arms
72,total ( n = nmbr nmbr ),arms;p-interaction,characteristic_level,total ( n = nmbr nmbr ),characteristic_level
73,nmbr,other;outcomes,characteristic_level,nmbr,characteristic_level
74,"post - cabg """,other;outcomes,characteristic_level,"post - cabg """,characteristic_level
75,woscops,other;outcomes,characteristic_name,woscops,characteristic_name
76,gissi prevention nmbr / nmbr - nmbr / nmbr,other;outcomes,characteristic_level,gissi prevention nmbr / nmbr - nmbr / nmbr,characteristic_level
77,allhat - llt,other;outcomes,characteristic_name,allhat - llt,characteristic_name
78,cards,other;outcomes,characteristic_name,cards,characteristic_name
79,afcaps /,other;outcomes,characteristic_name,afcaps /,characteristic_name
80,prosper,other;outcomes,characteristic_name,prosper,characteristic_name
81,lipid,other;outcomes,characteristic_name,lipid,characteristic_name
82,post - cabg,other;outcomes,characteristic_level,post - cabg,characteristic_level
83,lips,other;outcomes,characteristic_name,lips,characteristic_name
84,alert,other;outcomes,characteristic_name,alert,characteristic_name
85,total,other;outcomes,arms,total,arms
86,ascot - lla,other;outcomes,characteristic_name,ascot - lla,characteristic_name
87,care,other;outcomes,arms,care,arms
88,hps,other;outcomes,characteristic_name,hps,characteristic_name
89,"baseline history of vascular disease ( % ) """,measures;characteristic_name,characteristic_name,"baseline history of vascular disease ( % ) """,characteristic_name
90,baseline history of vascular disease ( % ),measures;characteristic_name,characteristic_name,baseline history of vascular disease ( % ),characteristic_name
91,heterogeneity / trend test,arms;other,characteristic_name,heterogeneity / trend test,characteristic_name
92,( % ) control ( nmbr ),arms;other,arms,( % ) control ( nmbr ),arms
93,"events treatment ( nmbr ) """,arms;other,measures,"events treatment ( nmbr ) """,measures
94,events treatment ( nmbr ),arms;other,measures,events treatment ( nmbr ),measures
95,rr ( cl ),arms;other,measures,rr ( cl ),measures
96,heterogeneity / trend test,arms;other;measures,characteristic_name,heterogeneity / trend test,characteristic_name
97,( % ) control ( nmbr ),arms;other;measures,arms,( % ) control ( nmbr ),arms
98,"events treatment ( nmbr ) """,arms;other;measures,measures,"events treatment ( nmbr ) """,measures
99,events treatment ( nmbr ),arms;other;measures,measures,events treatment ( nmbr ),measures
100,rr ( cl ),arms;other;measures,measures,rr ( cl ),measures
101,"white """,measures;characteristic_level,characteristic_level,"white """,characteristic_level
102,asian,measures;characteristic_level,characteristic_level,asian,characteristic_level
103,white,measures;characteristic_level,characteristic_level,white,characteristic_level
104,hispanic,measures;characteristic_level,characteristic_level,hispanic,characteristic_level
105,black,measures;characteristic_level,characteristic_level,black,characteristic_level
106,adjusted hr ( nmbr % cl ),arms;measures,measures,adjusted hr ( nmbr % cl ),measures
108,losartan,arms;measures,characteristic_name,losartan,characteristic_name
109,"adjusted hr ( nmbr % cl ) """,arms;measures,measures,"adjusted hr ( nmbr % cl ) """,measures
110,pre - specified hr ( nmbr % cl ),arms;measures,measures,pre - specified hr ( nmbr % cl ),measures
111,| interactior nmbr p,measures;p-interaction,characteristic_level,| interactior nmbr p,characteristic_level
112,nmbr - year rates in placebo groups,measures;p-interaction,arms,nmbr - year rates in placebo groups,arms
113,"nmbr - year rates in placebo groups """,measures;p-interaction,arms,"nmbr - year rates in placebo groups """,arms
114,number of patients,measures;p-interaction,measures,number of patients,measures
115,p value for interaction,measures;p-interaction,measures,p value for interaction,measures
116,"p value for interaction """,measures;p-interaction,measures,"p value for interaction """,measures
117,hr ( nmbr % ci ),measures;p-interaction,measures,hr ( nmbr % ci ),measures
118,diabetes mellitus,characteristic_level;arms,characteristic_level,diabetes mellitus,characteristic_level
119,metabolic syndrome *,characteristic_level;arms,characteristic_level,metabolic syndrome *,characteristic_level
120,"metabolic syndrome * """,characteristic_level;arms,characteristic_level,"metabolic syndrome * """,characteristic_level
121,neither pbo + statin eze + statin,characteristic_level;arms,arms,neither pbo + statin eze + statin,arms
122,"placebo ( n = nmbr ) """,arms;measures,arms,"placebo ( n = nmbr ) """,arms
123,placebo ( n = nmbr ),arms;measures,arms,placebo ( n = nmbr ),arms
124,abciximab ( n = nmbr ),arms;measures,arms,abciximab ( n = nmbr ),arms
130,etoricoxib,measures;arms,arms,etoricoxib,arms
131,diclofenac,measures;arms,arms,diclofenac,arms
132,"diclofenac """,measures;arms,arms,"diclofenac """,arms
133,history of upper,characteristic_name;characteristic_level,characteristic_name,history of upper,characteristic_name
134,other dmard use,characteristic_name;characteristic_level,characteristic_name,other dmard use,characteristic_name
135,"cox - nmbr selective inhibitor use """,characteristic_name;characteristic_level,characteristic_level,"cox - nmbr selective inhibitor use """,characteristic_level
136,methotrexate use,characteristic_name;characteristic_level,characteristic_name,methotrexate use,characteristic_name
137,< nmbr years,characteristic_name;characteristic_level,characteristic_level,< nmbr years,characteristic_level
138,rheumatoid arthritis,characteristic_name;characteristic_level,characteristic_name,rheumatoid arthritis,characteristic_name
139,age ( years ),characteristic_name;characteristic_level,characteristic_name,age ( years ),characteristic_name
140,> nmbr to < nmbr years,characteristic_name;characteristic_level,characteristic_level,> nmbr to < nmbr years,characteristic_level
141,low - dose aspirin use,characteristic_name;characteristic_level,characteristic_name,low - dose aspirin use,characteristic_name
142,traditional nsaid use,characteristic_name;characteristic_level,characteristic_name,traditional nsaid use,characteristic_name
143,systemic corticosteroid use,characteristic_name;characteristic_level,characteristic_name,systemic corticosteroid use,characteristic_name
144,cox - nmbr selective inhibitor use,characteristic_name;characteristic_level,characteristic_level,cox - nmbr selective inhibitor use,characteristic_level
145,> nmbr years,characteristic_name;characteristic_level,characteristic_level,> nmbr years,characteristic_level
146,sex ( female ),characteristic_name;characteristic_level,characteristic_name,sex ( female ),characteristic_name
147,ppi use,characteristic_name;characteristic_level,characteristic_name,ppi use,characteristic_name
148,cigarette smoker,characteristic_name;characteristic_level,characteristic_level,cigarette smoker,characteristic_level
149,osteoarthritis,characteristic_name;characteristic_level,characteristic_name,osteoarthritis,characteristic_name
150,hazard ratio ( nmbr % ci ),arms;measures,measures,hazard ratio ( nmbr % ci ),measures
151,"etoricoxib """,arms;measures,arms,"etoricoxib """,arms
152,etoricoxib,arms;measures,arms,etoricoxib,arms
153,diclofenac,arms;measures,arms,diclofenac,arms
154,interaction p,arms;measures;p-interaction,characteristic_name,interaction p,characteristic_name
155,control ( n = nmbr ),arms;measures;p-interaction,arms,control ( n = nmbr ),arms
156,hazard ratio ( nmbr % cl ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
157,"hazard ratio ( nmbr % cl ) """,arms;measures;p-interaction,measures,"hazard ratio ( nmbr % cl ) """,measures
158,epa ( n = nmbr ),arms;measures;p-interaction,arms,epa ( n = nmbr ),arms
159,"body mass index , median ( iqr )",characteristic_name;characteristic_level,characteristic_name,"body mass index , median ( iqr )",characteristic_name
160,prior heart failure,characteristic_name;characteristic_level,characteristic_name,prior heart failure,characteristic_name
161,unstable angina,characteristic_name;characteristic_level,characteristic_level,unstable angina,characteristic_level
162,other,characteristic_name;characteristic_level,characteristic_level,other,characteristic_level
163,aspirin,characteristic_name;characteristic_level,arms,aspirin,arms
164,statin,characteristic_name;characteristic_level,arms,statin,arms
165,thienopyridine,characteristic_name;characteristic_level,arms,thienopyridine,arms
166,hyperlipidemia,characteristic_name;characteristic_level,arms,hyperlipidemia,arms
167,nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level,nmbr - nmbr,characteristic_level
168,white race,characteristic_name;characteristic_level,characteristic_name,white race,characteristic_name
169,coronary angiography during the index hospitalization,characteristic_name;characteristic_level,characteristic_name,coronary angiography during the index hospitalization,characteristic_name
170,p - blocker,characteristic_name;characteristic_level,characteristic_level,p - blocker,characteristic_level
171,non - st - elevation ml,characteristic_name;characteristic_level,characteristic_level,non - st - elevation ml,characteristic_level
172,prior ml,characteristic_name;characteristic_level,characteristic_level,prior ml,characteristic_level
173,diabetes mellitus,characteristic_name;characteristic_level,characteristic_level,diabetes mellitus,characteristic_level
174,female sex,characteristic_name;characteristic_level,characteristic_name,female sex,characteristic_name
175,heparin,characteristic_name;characteristic_level,characteristic_level,heparin,characteristic_level
176,"time from onset of pain to randomization , median ( iqr ) , h",characteristic_name;characteristic_level,characteristic_name,"time from onset of pain to randomization , median ( iqr ) , h",characteristic_name
177,prior coronary revascularization,characteristic_name;characteristic_level,characteristic_level,prior coronary revascularization,characteristic_level
178,estimated creatinine clearance < nmbr ml / mint,characteristic_name;characteristic_level,characteristic_name,estimated creatinine clearance < nmbr ml / mint,characteristic_name
179,current smoker,characteristic_name;characteristic_level,characteristic_level,current smoker,characteristic_level
180,st - segment depression > nmbr . nmbr mv,characteristic_name;characteristic_level,characteristic_level,st - segment depression > nmbr . nmbr mv,characteristic_level
181,"weight , median ( iqr ) , kg",characteristic_name;characteristic_level,characteristic_level,"weight , median ( iqr ) , kg",characteristic_level
182,ace inhibitor or angiotensin ii receptor blocker,characteristic_name;characteristic_level,characteristic_level,ace inhibitor or angiotensin ii receptor blocker,characteristic_level
183,"female sex """,characteristic_name;characteristic_level,characteristic_name,"female sex """,characteristic_name
184,"age , median ( iqr ) , y",characteristic_name;characteristic_level,characteristic_level,"age , median ( iqr ) , y",characteristic_level
185,age > nmbr y,characteristic_name;characteristic_level,characteristic_name,age > nmbr y,characteristic_name
186,glycoprotein llb / llla receptor inhibitor,characteristic_name;characteristic_level,characteristic_level,glycoprotein llb / llla receptor inhibitor,characteristic_level
187,hypertension,characteristic_name;characteristic_level,characteristic_level,hypertension,characteristic_level
189,"certolizumab group ( n = nmbr ) """,arms;measures,arms,"certolizumab group ( n = nmbr ) """,arms
190,placebo group ( n = nmbr ) f,arms;measures,arms,placebo group ( n = nmbr ) f,arms
191,certolizumab group ( n = nmbr ),arms;measures,arms,certolizumab group ( n = nmbr ),arms
192,p - valuea,arms;measures,characteristic_name,p - valuea,characteristic_name
193,rrr ( nmbr % cl ),arms;measures,measures,rrr ( nmbr % cl ),measures
194,interactionnmbr,arms;measures,characteristic_name,interactionnmbr,characteristic_name
197,"placebo """,arms;measures,arms,"placebo """,arms
198,nmbr . nmbr,arms;measures,characteristic_level,nmbr . nmbr,characteristic_level
199,"nmbr . nmbr """,arms;measures,characteristic_level,"nmbr . nmbr """,characteristic_level
200,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),arms;measures,characteristic_level,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),characteristic_level
201,id genotype,measures;other,arms,id genotype,arms
202,p,measures;other,characteristic_name,p,characteristic_name
203,"id genotype """,measures;other,arms,"id genotype """,arms
204,"losartan , n / n ( % )",arms;measures;p-interaction,characteristic_name,"losartan , n / n ( % )",characteristic_name
205,"adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ) """,arms;measures;p-interaction,measures,"adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ) """,measures
206,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),arms;measures;p-interaction,measures,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),measures
207,"placebo , n / n ( % )",arms;measures;p-interaction,arms,"placebo , n / n ( % )",arms
208,f * >,arms;measures;p-interaction,characteristic_name,f * >,characteristic_name
209,"amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ) """,arms;other,arms,"amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ) """,arms
210,total study population ( n = nmbr ),arms;other,other,total study population ( n = nmbr ),other
211,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),arms;other,arms,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),arms
212,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),arms;other,arms,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),arms
214,"aspirin ( n = nmbr nmbr ) """,arms;measures,characteristic_level,"aspirin ( n = nmbr nmbr ) """,characteristic_level
215,aspirin ( n = nmbr nmbr ),arms;measures,characteristic_level,aspirin ( n = nmbr nmbr ),characteristic_level
216,placebo ( n = nmbr nmbr ),arms;measures,arms,placebo ( n = nmbr nmbr ),arms
218,"placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ) """,arms;measures,arms,"placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ) """,arms
219,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms;measures,arms,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms
220,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms;measures,characteristic_level,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),characteristic_level
221,hazard ratio * ( nmbr % ci ),arms;measures,measures,hazard ratio * ( nmbr % ci ),measures
222,bodymass index ( kg / mnmbr ),characteristic_name;characteristic_level,characteristic_name,bodymass index ( kg / mnmbr ),characteristic_name
223,serum pnmbrnp ( ^g / liter ),characteristic_name;characteristic_level,characteristic_level,serum pnmbrnp ( ^g / liter ),characteristic_level
224,< nmbr yr since menopause,characteristic_name;characteristic_level,characteristic_level,< nmbr yr since menopause,characteristic_level
225,lumbar spine bmd t - score,characteristic_name;characteristic_level,characteristic_name,lumbar spine bmd t - score,characteristic_name
226,serum ctx ( ng / ml ),characteristic_name;characteristic_level,characteristic_level,serum ctx ( ng / ml ),characteristic_level
227,"< nmbr yr since menopause """,characteristic_name;characteristic_level,characteristic_level,"< nmbr yr since menopause """,characteristic_level
228,years since menopause,characteristic_name;characteristic_level,characteristic_level,years since menopause,characteristic_level
229,serum trap - nmbrb ( u / liter ),characteristic_name;characteristic_level,characteristic_name,serum trap - nmbrb ( u / liter ),characteristic_name
230,age ( yr ),characteristic_name;characteristic_level,characteristic_level,age ( yr ),characteristic_level
231,> nmbr yr since menopause,characteristic_name;characteristic_level,characteristic_level,> nmbr yr since menopause,characteristic_level
233,denosumab ( n = nmbr ),arms;measures,characteristic_level,denosumab ( n = nmbr ),characteristic_level
234,"denosumab ( n = nmbr ) """,arms;measures,characteristic_level,"denosumab ( n = nmbr ) """,characteristic_level
235,all ( n = nmbr ),arms;measures,characteristic_level,all ( n = nmbr ),characteristic_level
236,no,characteristic_name;characteristic_level,characteristic_level,no,characteristic_level
237,gender male,characteristic_name;characteristic_level,characteristic_level,gender male,characteristic_level
238,sbp ( mmhg ) < nmbr,characteristic_name;characteristic_level,characteristic_name,sbp ( mmhg ) < nmbr,characteristic_name
239,ale < nmbr,characteristic_name;characteristic_level,characteristic_level,ale < nmbr,characteristic_level
240,egfr < nmbr,characteristic_name;characteristic_level,characteristic_level,egfr < nmbr,characteristic_level
241,> nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr,characteristic_level
242,nmbr . nmbr - nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,nmbr . nmbr - nmbr . nmbr,characteristic_level
243,ldl - c ( mg / dl ) < nmbr,characteristic_name;characteristic_level,characteristic_level,ldl - c ( mg / dl ) < nmbr,characteristic_level
244,bmi ( kg / mnmbr ) < nmbr,characteristic_name;characteristic_level,characteristic_level,bmi ( kg / mnmbr ) < nmbr,characteristic_level
245,"> nmbr """,characteristic_name;characteristic_level,characteristic_level,"> nmbr """,characteristic_level
246,age ( yrs ) < nmbr,characteristic_name;characteristic_level,characteristic_level,age ( yrs ) < nmbr,characteristic_level
247,female,characteristic_name;characteristic_level,characteristic_level,female,characteristic_level
248,current smoker yes,characteristic_name;characteristic_level,characteristic_level,current smoker yes,characteristic_level
249,crp ( mg / dl ) < nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,crp ( mg / dl ) < nmbr . nmbr,characteristic_level
250,> nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr . nmbr,characteristic_level
252,non - hdl ( mg / dl ) < nmbr,characteristic_name;characteristic_level,characteristic_level,non - hdl ( mg / dl ) < nmbr,characteristic_level
253,no epa group n = nmbr,arms;measures,arms,no epa group n = nmbr,arms
255,"epa group n = nmbr """,arms;measures,arms,"epa group n = nmbr """,arms
256,epa group n = nmbr,arms;measures,arms,epa group n = nmbr,arms
257,p value,measures;p-interaction,measures,p value,measures
258,"hr , nmbr % cl",measures;p-interaction,measures,"hr , nmbr % cl",measures
259,"p value """,measures;p-interaction,measures,"p value """,measures
260,epa group no . of events ( % ),measures;p-interaction,arms,epa group no . of events ( % ),arms
261,no epa group no . of events ( % ),measures;p-interaction,arms,no epa group no . of events ( % ),arms
262,placebo group ( n = nmbr ),measures;arms,arms,placebo group ( n = nmbr ),arms
263,"placebo group ( n = nmbr ) """,measures;arms,arms,"placebo group ( n = nmbr ) """,arms
264,metoprolol group ( n = nmbr ),measures;arms,arms,metoprolol group ( n = nmbr ),arms
265,"valsartan ( n = nmbr ) """,arms;p-interaction,arms,"valsartan ( n = nmbr ) """,arms
266,valsartan ( n = nmbr ),arms;p-interaction,arms,valsartan ( n = nmbr ),arms
267,p *,arms;p-interaction,characteristic_name,p *,characteristic_name
268,valsartan / hctz ( n = nmbr ),arms;p-interaction,arms,valsartan / hctz ( n = nmbr ),arms
269,"valsartan , n / n ( % )",p-interaction;arms,arms,"valsartan , n / n ( % )",arms
270,p *,p-interaction;arms,characteristic_name,p *,characteristic_name
271,"valsartan / hctz , n / n ( % ) """,p-interaction;arms,arms,"valsartan / hctz , n / n ( % ) """,arms
272,"valsartan / hctz , n / n ( % )",p-interaction;arms,arms,"valsartan / hctz , n / n ( % )",arms
273,valsartan / hctz,arms;p-interaction,arms,valsartan / hctz,arms
274,p,arms;p-interaction,characteristic_name,p,characteristic_name
275,valsartan,arms;p-interaction,arms,valsartan,arms
276,"valsartan / hctz """,arms;p-interaction,arms,"valsartan / hctz """,arms
277,usual care ( n = nmbrla ),arms;measures,arms,usual care ( n = nmbrla ),arms
278,proactive intervention ( n = nmbra ),arms;measures,characteristic_name,proactive intervention ( n = nmbra ),characteristic_name
279,usual care ( n = nmbra ),arms;measures,arms,usual care ( n = nmbra ),arms
280,"usual care ( n = nmbrla ) """,arms;measures,arms,"usual care ( n = nmbrla ) """,arms
281,p valuenmbr,arms;measures,characteristic_name,p valuenmbr,characteristic_name
282,intensive control ( n = nmbr ) no . of patients ( percent ),arms;measures,measures,intensive control ( n = nmbr ) no . of patients ( percent ),measures
283,"standard control ( n = nmbr ) no . of patients ( percent ) """,arms;measures,arms,"standard control ( n = nmbr ) no . of patients ( percent ) """,arms
284,relative risk reduction ( nmbr % cl ) percent,arms;measures,measures,relative risk reduction ( nmbr % cl ) percent,measures
285,standard control ( n = nmbr ) no . of patients ( percent ),arms;measures,arms,standard control ( n = nmbr ) no . of patients ( percent ),arms
286,atenolol n = nmbr no . ( % ),arms;measures,characteristic_level,atenolol n = nmbr no . ( % ),characteristic_level
287,"atenolol n = nmbr no . ( % ) """,arms;measures,characteristic_level,"atenolol n = nmbr no . ( % ) """,characteristic_level
288,hr ( nmbr % cl ),arms;measures,measures,hr ( nmbr % cl ),measures
289,verapamil sr n = nmbr no . ( % ),arms;measures,arms,verapamil sr n = nmbr no . ( % ),arms
290,"aspirin - erdp clopidogrel no . of patients / total no . """,arms;measures,arms,"aspirin - erdp clopidogrel no . of patients / total no . """,arms
291,aspirin - erdp clopidogrel no . of patients / total no .,arms;measures,arms,aspirin - erdp clopidogrel no . of patients / total no .,arms
292,hr ( nmbr % cl ) *,arms;measures,measures,hr ( nmbr % cl ) *,measures
293,rosuvastatin events / patients ( % ),arms;measures,measures,rosuvastatin events / patients ( % ),measures
294,"placebo events / patients ( % ) """,arms;measures,measures,"placebo events / patients ( % ) """,measures
295,placebo events / patients ( % ),arms;measures,measures,placebo events / patients ( % ),measures
299,n - nmbr pufa events / patients ( % ),arms;measures,measures,n - nmbr pufa events / patients ( % ),measures
300,p inleraclion,arms;measures;p-interaction,characteristic_name,p inleraclion,characteristic_name
302,aspirin group,arms;measures;p-interaction,arms,aspirin group,arms
303,rr ( nmbr % ci ) *,arms;measures;p-interaction,measures,rr ( nmbr % ci ) *,measures
304,"rr ( nmbr % ci ) * """,arms;measures;p-interaction,measures,"rr ( nmbr % ci ) * """,measures
305,placebo,arms;p-interaction,arms,placebo,arms
306,p value for interaction,arms;p-interaction,measures,p value for interaction,measures
307,irbesartan,arms;p-interaction,arms,irbesartan,arms
308,"irbesartan """,arms;p-interaction,arms,"irbesartan """,arms
309,"india """,characteristic_name;characteristic_level,characteristic_level,"india """,characteristic_level
310,hbanmbrc ( % ) all countries,characteristic_name;characteristic_level,characteristic_name,hbanmbrc ( % ) all countries,characteristic_name
311,india,characteristic_name;characteristic_level,characteristic_level,india,characteristic_level
312,china,characteristic_name;characteristic_level,arms,china,arms
313,all countries,characteristic_name;characteristic_level,outcomes,all countries,outcomes
314,korea,characteristic_name;characteristic_level,arms,korea,arms
315,aliskiren ( n = nmbr ),arms;measures,arms,aliskiren ( n = nmbr ),arms
316,"hydochlorothiazide ( n = nmbr ) """,arms;measures,characteristic_level,"hydochlorothiazide ( n = nmbr ) """,characteristic_level
318,hydochlorothiazide ( n = nmbr ),arms;measures,characteristic_level,hydochlorothiazide ( n = nmbr ),characteristic_level
323,value for nteraction,measures;p-interaction,measures,value for nteraction,measures
324,"value for nteraction """,measures;p-interaction,measures,"value for nteraction """,measures
326,"ranozaline """,arms;measures,characteristic_name,"ranozaline """,characteristic_name
327,hr,arms;measures,measures,hr,measures
328,ranozaline,arms;measures,characteristic_name,ranozaline,characteristic_name
332,"placebo """,arms;p-interaction,arms,"placebo """,arms
333,sal nmbr mg,arms;measures,arms,sal nmbr mg,arms
335,sfc nmbr mg / nmbr mg,arms;measures,arms,sfc nmbr mg / nmbr mg,arms
336,fp nmbr mg,arms;measures,arms,fp nmbr mg,arms
337,total,arms;measures,arms,total,arms
339,fpg ( mg / dl ),outcomes;measures,outcomes,fpg ( mg / dl ),outcomes
340,"systolic ( mmhg ) """,outcomes;measures,arms,"systolic ( mmhg ) """,arms
341,hdl - cholesterol ( mg / dl ),outcomes;measures,characteristic_name,hdl - cholesterol ( mg / dl ),characteristic_name
342,epa ( mol % ),outcomes;measures,arms,epa ( mol % ),arms
343,ldl - cholesterol ( mg / dl ),outcomes;measures,characteristic_name,ldl - cholesterol ( mg / dl ),characteristic_name
344,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],outcomes;measures,characteristic_level,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],characteristic_level
345,systolic ( mmhg ),outcomes;measures,arms,systolic ( mmhg ),arms
346,"hba , c ( % )",outcomes;measures,characteristic_name,"hba , c ( % )",characteristic_name
347,total cholesterol ( mg / dl ),outcomes;measures,characteristic_name,total cholesterol ( mg / dl ),characteristic_name
348,diastolic fmmhff ' ),outcomes;measures,characteristic_name,diastolic fmmhff ' ),characteristic_name
349,epa hr events ( % ),arms;measures,measures,epa hr events ( % ),measures
351,non - epa number of <,arms;measures,arms,non - epa number of <,arms
353,"non - epa number of < """,arms;measures,arms,"non - epa number of < """,arms
354,"p value for trend """,characteristic_name;p-interaction,measures,"p value for trend """,measures
355,mmse score,characteristic_name;p-interaction,characteristic_name,mmse score,characteristic_name
356,p value for trend,characteristic_name;p-interaction,measures,p value for trend,measures
357,"all participants """,characteristic_name;characteristic_level,measures,"all participants """,measures
358,mmse < nmbr,characteristic_name;characteristic_level,characteristic_name,mmse < nmbr,characteristic_name
359,mmse > nmbr,characteristic_name;characteristic_level,characteristic_name,mmse > nmbr,characteristic_name
360,all participants,characteristic_name;characteristic_level,measures,all participants,measures
361,mmse nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level,mmse nmbr - nmbr,characteristic_level
362,ischemic aetiology,characteristic_level;characteristic_name,outcomes,ischemic aetiology,outcomes
363,nyha ii,characteristic_level;characteristic_name,characteristic_level,nyha ii,characteristic_level
364,age > nmbr yearsnmbr,characteristic_level;characteristic_name,characteristic_name,age > nmbr yearsnmbr,characteristic_name
365,history of paroxysmal af,characteristic_level;characteristic_name,characteristic_name,history of paroxysmal af,characteristic_name
366,non - ischaemic aetiology,characteristic_level;characteristic_name,characteristic_level,non - ischaemic aetiology,characteristic_level
367,total cholesterolnmbr > nmbr mg / dl,characteristic_level;characteristic_name,arms,total cholesterolnmbr > nmbr mg / dl,arms
368,diabetes,characteristic_level;characteristic_name,characteristic_level,diabetes,characteristic_level
369,lvef < nmbr %,characteristic_level;characteristic_name,characteristic_level,lvef < nmbr %,characteristic_level
370,no history of paroxysmal af,characteristic_level;characteristic_name,characteristic_name,no history of paroxysmal af,characteristic_name
371,total cholesterolnmbr < nmbr mg / dl,characteristic_level;characteristic_name,arms,total cholesterolnmbr < nmbr mg / dl,arms
372,lvef > nmbr %,characteristic_level;characteristic_name,characteristic_level,lvef > nmbr %,characteristic_level
373,nyha lll - iv,characteristic_level;characteristic_name,characteristic_level,nyha lll - iv,characteristic_level
374,"no history of paroxysmal af """,characteristic_level;characteristic_name,characteristic_name,"no history of paroxysmal af """,characteristic_name
375,no diabetes,characteristic_level;characteristic_name,characteristic_level,no diabetes,characteristic_level
376,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level;characteristic_name,characteristic_level,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level
377,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level;characteristic_name,characteristic_level,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level
378,age < nmbr yearsnmbr,characteristic_level;characteristic_name,characteristic_name,age < nmbr yearsnmbr,characteristic_name
379,p value for heterogeneity,arms;p-interaction,measures,p value for heterogeneity,measures
380,fluvastatin ( n = nmbr ),arms;p-interaction,characteristic_level,fluvastatin ( n = nmbr ),characteristic_level
381,"fluvastatin ( n = nmbr ) """,arms;p-interaction,characteristic_level,"fluvastatin ( n = nmbr ) """,characteristic_level
382,placebo ( n = nmbr ),arms;p-interaction,arms,placebo ( n = nmbr ),arms
383,reteplase / abciximab - facilitated pci ( n = nmbr ),arms;measures,arms,reteplase / abciximab - facilitated pci ( n = nmbr ),arms
384,"primary pci ( n = nmbr ) """,arms;measures,outcomes,"primary pci ( n = nmbr ) """,outcomes
386,abciximab - facilitated pci ( n = nmbr ),arms;measures,arms,abciximab - facilitated pci ( n = nmbr ),arms
387,primary pci ( n = nmbr ),arms;measures,outcomes,primary pci ( n = nmbr ),outcomes
388,nmbr % cinmbr,arms;measures;p-interaction,characteristic_level,nmbr % cinmbr,characteristic_level
389,interaction p - valuenmbr,arms;measures;p-interaction,characteristic_name,interaction p - valuenmbr,characteristic_name
390,"hazard rationmbr """,arms;measures;p-interaction,measures,"hazard rationmbr """,measures
391,rosuvastatin n ( rate ) nmbr,arms;measures;p-interaction,measures,rosuvastatin n ( rate ) nmbr,measures
392,placebo n ( rate ) nmbr,arms;measures;p-interaction,arms,placebo n ( rate ) nmbr,arms
393,hazard rationmbr,arms;measures;p-interaction,measures,hazard rationmbr,measures
394,subgroup p - valuenmbr,arms;measures;p-interaction,characteristic_level,subgroup p - valuenmbr,characteristic_level
395,"p , interaction !",arms;measures;p-interaction,characteristic_name,"p , interaction !",characteristic_name
396,"p , subgroup *",arms;measures;p-interaction,characteristic_level,"p , subgroup *",characteristic_level
397,"p , subgroup * """,arms;measures;p-interaction,characteristic_level,"p , subgroup * """,characteristic_level
398,"rosuvastatin , n ( rate )",arms;measures;p-interaction,measures,"rosuvastatin , n ( rate )",measures
399,"placebo , n ( rate )",arms;measures;p-interaction,arms,"placebo , n ( rate )",arms
400,hr ( nmbr % cl ),arms;measures;p-interaction,measures,hr ( nmbr % cl ),measures
401,azathioprine ( n = nmbr ),arms;measures,characteristic_level,azathioprine ( n = nmbr ),characteristic_level
402,infliximab ( n = nmbr ),arms;measures,arms,infliximab ( n = nmbr ),arms
403,all patients ( n = nmbr ),arms;measures,characteristic_level,all patients ( n = nmbr ),characteristic_level
404,combination therapy ( n = nmbr ),arms;measures,characteristic_name,combination therapy ( n = nmbr ),characteristic_name
405,"azathioprine ( n = nmbr ) """,arms;measures,characteristic_level,"azathioprine ( n = nmbr ) """,characteristic_level
406,p valued,arms;measures,characteristic_name,p valued,characteristic_name
407,"control """,arms;measures,arms,"control """,arms
408,control,arms;measures,arms,control,arms
409,difference,arms;measures,measures,difference,measures
410,control,measures;arms,arms,control,arms
411,tiotropium,measures;arms,arms,tiotropium,arms
412,mean yearly decline,measures;arms,measures,mean yearly decline,measures
413,"mean yearly decline """,measures;arms,measures,"mean yearly decline """,measures
414,events,arms;measures,measures,events,measures
415,"n """,arms;measures,characteristic_name,"n """,characteristic_name
416,n,arms;measures,characteristic_name,n,characteristic_name
417,macce ( % ) abciximab placebo,arms;measures;p-interaction,arms,macce ( % ) abciximab placebo,arms
418,p value for interaction,arms;measures;p-interaction,measures,p value for interaction,measures
419,relative risk ( nmbr % confidence interval ),arms;measures;p-interaction,measures,relative risk ( nmbr % confidence interval ),measures
420,"macce ( % ) abciximab placebo """,arms;measures;p-interaction,arms,"macce ( % ) abciximab placebo """,arms
421,"absolute risk difference ( ci ) , % *",arms;measures,measures,"absolute risk difference ( ci ) , % *",measures
422,"extended - duration enoxaparin , n / n ( % )",arms;measures,arms,"extended - duration enoxaparin , n / n ( % )",arms
423,"placebo , n / n ( % )",arms;measures,arms,"placebo , n / n ( % )",arms
424,"placebo , n / n ( % ) """,arms;measures,arms,"placebo , n / n ( % ) """,arms
426,salmeterol ( n[nmbr ),arms;measures,arms,salmeterol ( n[nmbr ),arms
427,placebo ( n[nmbr ),arms;measures,arms,placebo ( n[nmbr ),arms
428,sfc ( n[nmbr ),arms;measures,measures,sfc ( n[nmbr ),measures
429,fp ( n[nmbr ),arms;measures,characteristic_level,fp ( n[nmbr ),characteristic_level
431,ivabradine group,arms;measures,arms,ivabradine group,arms
433,placebo group,arms;measures,arms,placebo group,arms
434,"ivabradine group """,arms;measures,arms,"ivabradine group """,arms
435,"all with coenzyme qnmbr ( n = nmbr , nmbr )",characteristic_level;measures,arms,"all with coenzyme qnmbr ( n = nmbr , nmbr )",arms
436,p value for trend across tertiles,characteristic_level;measures,measures,p value for trend across tertiles,measures
437,"tertile nmbr ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"tertile nmbr ( n = nmbr ) """,characteristic_level
438,tertile nmbr ( n = nmbr ),characteristic_level;measures,characteristic_level,tertile nmbr ( n = nmbr ),characteristic_level
439,"tertile nmbr """,outcomes;characteristic_level,characteristic_level,"tertile nmbr """,characteristic_level
440,all randomized all - cause mortality,outcomes;characteristic_level,outcomes,all randomized all - cause mortality,outcomes
441,all randomized coronary end point,outcomes;characteristic_level,characteristic_name,all randomized coronary end point,characteristic_name
442,primary end point |,outcomes;characteristic_level,measures,primary end point |,measures
443,all randomized,outcomes;characteristic_level,outcomes,all randomized,outcomes
444,tertile nmbr,outcomes;characteristic_level,characteristic_level,tertile nmbr,characteristic_level
445,all randomized all - cause mortality or hospitalization for worsening hf^,outcomes;characteristic_level,outcomes,all randomized all - cause mortality or hospitalization for worsening hf^,outcomes
447,rolofylline,arms;measures,characteristic_name,rolofylline,characteristic_name
449,"imm + corticosteroid , n",measures;characteristic_level,characteristic_level,"imm + corticosteroid , n",characteristic_level
450,"extensive colitis , n",measures;characteristic_level,characteristic_level,"extensive colitis , n",characteristic_level
451,"no aminosalicylates , n",measures;characteristic_level,characteristic_level,"no aminosalicylates , n",characteristic_level
452,"mayo $ nmbr , n",measures;characteristic_level,characteristic_level,"mayo $ nmbr , n",characteristic_level
453,"weight < nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level,"weight < nmbr . nmbr kg , n",characteristic_level
454,"remission , n ( % )",measures;characteristic_level,arms,"remission , n ( % )",arms
455,"no corticosteroid + no imm , n",measures;characteristic_level,characteristic_level,"no corticosteroid + no imm , n",characteristic_level
456,"difference from placebo ( nmbr % ci ) """,measures;characteristic_level,measures,"difference from placebo ( nmbr % ci ) """,measures
457,difference from placebo * ( nmbr % ci ),measures;characteristic_level,measures,difference from placebo * ( nmbr % ci ),measures
458,"immy ( without corticosteroid ) , n",measures;characteristic_level,characteristic_level,"immy ( without corticosteroid ) , n",characteristic_level
459,"weight $ nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level,"weight $ nmbr . nmbr kg , n",characteristic_level
460,"no extensive colitis , n",measures;characteristic_level,characteristic_level,"no extensive colitis , n",characteristic_level
461,"crp $ nmbr mg / l , n",measures;characteristic_level,arms,"crp $ nmbr mg / l , n",arms
462,difference from placebo ( nmbr % ci ),measures;characteristic_level,measures,difference from placebo ( nmbr % ci ),measures
463,"corticosteroid ( without imm ) , n",measures;characteristic_level,characteristic_level,"corticosteroid ( without imm ) , n",characteristic_level
464,"aminosalicylates , n",measures;characteristic_level,arms,"aminosalicylates , n",arms
465,"crp < nmbr mg / l , n",measures;characteristic_level,arms,"crp < nmbr mg / l , n",arms
466,"mayo < nmbr , n",measures;characteristic_level,characteristic_level,"mayo < nmbr , n",characteristic_level
467,"weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level,"weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n",characteristic_level
468,bosentan,arms;measures,characteristic_name,bosentan,characteristic_name
471,"bosentan """,arms;measures,characteristic_name,"bosentan """,characteristic_name
472,nmbr % cl,arms;measures,measures,nmbr % cl,measures
474,sal ( n = nmbr ),arms;measures,characteristic_level,sal ( n = nmbr ),characteristic_level
475,"sal ( n = nmbr ) """,arms;measures,characteristic_level,"sal ( n = nmbr ) """,characteristic_level
476,sfc ( n = nmbr ),arms;measures,measures,sfc ( n = nmbr ),measures
477,total ho population ( n = nmbr ),arms;measures,other,total ho population ( n = nmbr ),other
478,total population ( n = nmbr ),arms;measures,other,total population ( n = nmbr ),other
479,fp ( n = nmbr ),arms;measures,characteristic_level,fp ( n = nmbr ),characteristic_level
480,r | r ' ' ' ( nmbr % ci ),arms;measures,measures,r | r ' ' ' ( nmbr % ci ),measures
481,asa,arms;measures,characteristic_level,asa,characteristic_level
483,"pla """,arms;measures,arms,"pla """,arms
484,rr^ ( nmbr % ci ),arms;measures,measures,rr^ ( nmbr % ci ),measures
485,mean ( sd ),characteristic_level;measures,characteristic_level,mean ( sd ),characteristic_level
486,male,characteristic_level;measures,characteristic_level,male,characteristic_level
487,history of pci,characteristic_level;measures,characteristic_name,history of pci,characteristic_name
488,hyperlipidemia^,characteristic_level;measures,arms,hyperlipidemia^,arms
489,range,characteristic_level;measures,characteristic_level,range,characteristic_level
490,current smoker,characteristic_level;measures,characteristic_level,current smoker,characteristic_level
491,diabetes mellitus,characteristic_level;measures,characteristic_level,diabetes mellitus,characteristic_level
492,hypertension *,characteristic_level;measures,characteristic_level,hypertension *,characteristic_level
493,history of carotid artery disease,characteristic_level;measures,characteristic_name,history of carotid artery disease,characteristic_name
494,history of peripheral artery disease,characteristic_level;measures,characteristic_name,history of peripheral artery disease,characteristic_name
495,"history of pci """,characteristic_level;measures,characteristic_name,"history of pci """,characteristic_name
496,history of chd,characteristic_level;measures,characteristic_name,history of chd,characteristic_name
497,p,p-interaction;other,characteristic_name,p,characteristic_name
498,group a ( n = nmbr ),p-interaction;other,arms,group a ( n = nmbr ),arms
499,group c ( n = nmbr ),p-interaction;other,arms,group c ( n = nmbr ),arms
500,group b ( n = nmbr ),p-interaction;other,arms,group b ( n = nmbr ),arms
501,"group c ( n = nmbr ) """,p-interaction;other,arms,"group c ( n = nmbr ) """,arms
502,"total comparators , patients with events / total patients",measures;arms,measures,"total comparators , patients with events / total patients",measures
503,cox hr ( nmbr % ci ),measures;arms,measures,cox hr ( nmbr % ci ),measures
504,cmh rr ( nmbr % ci ),measures;arms,measures,cmh rr ( nmbr % ci ),measures
505,"cmh rr ( nmbr % ci ) """,measures;arms,measures,"cmh rr ( nmbr % ci ) """,measures
506,"linagliptin , patients with events / total patients",measures;arms,measures,"linagliptin , patients with events / total patients",measures
507,p - value for interaction,arms;measures;p-interaction,measures,p - value for interaction,measures
508,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )",arms;measures;p-interaction,measures,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )",measures
509,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr ) """,arms;measures;p-interaction,measures,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr ) """,measures
510,vorapaxar placebo nmbr - yr %,arms;measures;p-interaction,arms,vorapaxar placebo nmbr - yr %,arms
511,p - value for interaction,arms;p-interaction,measures,p - value for interaction,measures
512,"p - value for interaction """,arms;p-interaction,measures,"p - value for interaction """,measures
513,p value,characteristic_level;measures,measures,p value,measures
514,nonmetabolic syndrome ( n = nmbr ),characteristic_level;measures,characteristic_level,nonmetabolic syndrome ( n = nmbr ),characteristic_level
515,"nonmetabolic syndrome ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"nonmetabolic syndrome ( n = nmbr ) """,characteristic_level
516,metabolic syndrome ( n = nmbr ),characteristic_level;measures,characteristic_level,metabolic syndrome ( n = nmbr ),characteristic_level
517,"patients without ra , as , or psa ( n = nmbr , nmbr )",arms;measures,characteristic_level,"patients without ra , as , or psa ( n = nmbr , nmbr )",characteristic_level
518,"patients with ra , as , or psa ( n = nmbr )",arms;measures,characteristic_level,"patients with ra , as , or psa ( n = nmbr )",characteristic_level
520,"patients without ra , as , or psa ( n = nmbr , nmbr ) """,arms;measures,characteristic_level,"patients without ra , as , or psa ( n = nmbr , nmbr ) """,characteristic_level
521,"atorvastatin nmbr mg ( n = nmbr , nmbr )",arms;measures,arms,"atorvastatin nmbr mg ( n = nmbr , nmbr )",arms
522,atorvastatin nmbr mg ( n = nmbr ),arms;measures,arms,atorvastatin nmbr mg ( n = nmbr ),arms
523,simvastatin nmbr mg ( n = nmbr ),arms;measures,arms,simvastatin nmbr mg ( n = nmbr ),arms
524,p +,arms;measures,characteristic_name,p +,characteristic_name
525,"pt """,arms;measures,measures,"pt """,measures
526,"simvastatin nmbr mg ( n = nmbr , nmbr )",arms;measures,arms,"simvastatin nmbr mg ( n = nmbr , nmbr )",arms
528,p,measures;arms,characteristic_name,p,characteristic_name
529,insulin glargine n ( % ) / nmbrpy,measures;arms,arms,insulin glargine n ( % ) / nmbrpy,arms
530,"hr ( nmbr % cl ) """,measures;arms,measures,"hr ( nmbr % cl ) """,measures
531,standard care n ( % ) / nmbrpy,measures;arms,arms,standard care n ( % ) / nmbrpy,arms
532,hr ( nmbr % cl ),measures;arms,measures,hr ( nmbr % cl ),measures
534,diabeticnmbr,characteristic_level;measures,characteristic_name,diabeticnmbr,characteristic_name
535,median,characteristic_level;measures,characteristic_level,median,characteristic_level
536,prediabeticb,characteristic_level;measures,characteristic_name,prediabeticb,characteristic_name
537,"egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )",characteristic_level;measures,characteristic_level,"egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )",characteristic_level
538,"age , y , mean ( sd )",characteristic_level;measures,characteristic_name,"age , y , mean ( sd )",characteristic_name
539,normoglycemicnmbr,characteristic_level;measures,characteristic_name,normoglycemicnmbr,characteristic_name
540,"> nmbr y , no . ( % )",characteristic_level;measures,characteristic_level,"> nmbr y , no . ( % )",characteristic_level
541,"normoglycemicnmbr """,characteristic_level;measures,characteristic_name,"normoglycemicnmbr """,characteristic_name
542,"hbanmbrc , % , mean ( sd )",characteristic_level;measures,characteristic_name,"hbanmbrc , % , mean ( sd )",characteristic_name
548,hr ( nmbr % ci ) p value for interaction *,arms;measures,measures,hr ( nmbr % ci ) p value for interaction *,measures
549,"vorapaxar placebo nmbr - yr . km % """,arms;measures,arms,"vorapaxar placebo nmbr - yr . km % """,arms
550,vorapaxar placebo nmbr - yr . km %,arms;measures,arms,vorapaxar placebo nmbr - yr . km %,arms
551,"age , years",characteristic_name;characteristic_level,characteristic_name,"age , years",characteristic_name
552,"duration of copd , years",characteristic_name;characteristic_level,characteristic_name,"duration of copd , years",characteristic_name
553,"fevnmbr ( post - albuterol ) , l",characteristic_name;characteristic_level,characteristic_name,"fevnmbr ( post - albuterol ) , l",characteristic_name
555,fevnmbr / fvc ( post - albuterol ),characteristic_name;characteristic_level,characteristic_name,fevnmbr / fvc ( post - albuterol ),characteristic_name
556,"ex - smoker / smoker , %",characteristic_name;characteristic_level,characteristic_name,"ex - smoker / smoker , %",characteristic_name
557,"ics use , yes / no %",characteristic_name;characteristic_level,characteristic_level,"ics use , yes / no %",characteristic_level
558,baseline dyspnea index score,characteristic_name;characteristic_level,characteristic_name,baseline dyspnea index score,characteristic_name
559,"sex , male / female , %",characteristic_name;characteristic_level,characteristic_level,"sex , male / female , %",characteristic_level
560,baseline sgrq score,characteristic_name;characteristic_level,characteristic_name,baseline sgrq score,characteristic_name
561,"fevnmbr reversibility , % b",characteristic_name;characteristic_level,characteristic_name,"fevnmbr reversibility , % b",characteristic_name
562,"severity of copd , n ( % ) ( gold nmbr ) : moderate",characteristic_name;characteristic_level,characteristic_name,"severity of copd , n ( % ) ( gold nmbr ) : moderate",characteristic_name
563,"fevnmbr % pred . ( post - albuterol ) , %",characteristic_name;characteristic_level,characteristic_name,"fevnmbr % pred . ( post - albuterol ) , %",characteristic_name
564,"age , years """,characteristic_name;characteristic_level,characteristic_name,"age , years """,characteristic_name
565,"smoking history , pack - years",characteristic_name;characteristic_level,characteristic_name,"smoking history , pack - years",characteristic_name
566,"fevnmbr ( pre - albuterol ) , l",characteristic_name;characteristic_level,characteristic_name,"fevnmbr ( pre - albuterol ) , l",characteristic_name
567,black,characteristic_name;characteristic_level,characteristic_level,black,characteristic_level
568,"race , % caucasian",characteristic_name;characteristic_level,characteristic_name,"race , % caucasian",characteristic_name
569,asian,characteristic_name;characteristic_level,characteristic_level,asian,characteristic_level
570,severe / very severea,characteristic_name;characteristic_level,characteristic_level,severe / very severea,characteristic_level
571,"sgrq total score ( week """,outcomes;measures,other,"sgrq total score ( week """,other
572,( baseline ),outcomes;measures,characteristic_name,( baseline ),characteristic_name
573,tdi total score ( week nmbr,outcomes;measures,other,tdi total score ( week nmbr,other
574,sgrq total score,outcomes;measures,arms,sgrq total score,arms
575,sgrq total score ( week,outcomes;measures,other,sgrq total score ( week,other
576,locf ),outcomes;measures,characteristic_name,locf ),characteristic_name
577,nmbr locf ),outcomes;measures,characteristic_level,nmbr locf ),characteristic_level
578,change from baseline,outcomes;measures,measures,change from baseline,measures
579,bdi total score ( baseline ),outcomes;measures,characteristic_name,bdi total score ( baseline ),characteristic_name
581,korean,characteristic_name;characteristic_level,arms,korean,arms
582,"fevnmbr , % predicteda",characteristic_name;characteristic_level,characteristic_name,"fevnmbr , % predicteda",characteristic_name
583,"male / female , %",characteristic_name;characteristic_level,characteristic_level,"male / female , %",characteristic_level
584,"copd severity , n ( % )",characteristic_name;characteristic_level,characteristic_name,"copd severity , n ( % )",characteristic_name
586,"fevnmbr / fvc , % a",characteristic_name;characteristic_level,characteristic_name,"fevnmbr / fvc , % a",characteristic_name
587,taiwan,characteristic_name;characteristic_level,characteristic_name,taiwan,characteristic_name
588,"fevnmbr , la",characteristic_name;characteristic_level,characteristic_name,"fevnmbr , la",characteristic_name
589,"ics use , %",characteristic_name;characteristic_level,characteristic_name,"ics use , %",characteristic_name
590,"duration of copd ,",characteristic_name;characteristic_level,characteristic_name,"duration of copd ,",characteristic_name
591,reversibility to,characteristic_name;characteristic_level,characteristic_name,reversibility to,characteristic_name
592,ex - smoker / current,characteristic_name;characteristic_level,characteristic_level,ex - smoker / current,characteristic_level
593,"smoking history ,",characteristic_name;characteristic_level,characteristic_name,"smoking history ,",characteristic_name
594,japanese,characteristic_name;characteristic_level,characteristic_name,japanese,characteristic_name
595,indian,characteristic_name;characteristic_level,characteristic_level,indian,characteristic_level
596,"smoking history , """,characteristic_name;characteristic_level,characteristic_name,"smoking history , """,characteristic_name
597,"conventional treatment """,arms;p-interaction;other,characteristic_name,"conventional treatment """,characteristic_name
598,conventional treatment,arms;p-interaction;other,characteristic_name,conventional treatment,characteristic_name
599,r elative risk ( nmbr % ci ),arms;p-interaction;other,measures,r elative risk ( nmbr % ci ),measures
600,m o nito ring treatment,arms;p-interaction;other,measures,m o nito ring treatment,measures
601,p interaction,arms;p-interaction;other,characteristic_name,p interaction,characteristic_name
602,"r elative risk ( nmbr % ci ) """,arms;other;p-interaction,measures,"r elative risk ( nmbr % ci ) """,measures
603,conventional treatment,arms;other;p-interaction,characteristic_name,conventional treatment,characteristic_name
604,r elative risk ( nmbr % ci ),arms;other;p-interaction,measures,r elative risk ( nmbr % ci ),measures
605,m o nito ring treatment,arms;other;p-interaction,measures,m o nito ring treatment,measures
606,p interaction,arms;other;p-interaction,characteristic_name,p interaction,characteristic_name
607,habitual fish intake : < nmbr servings / wk ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,habitual fish intake : < nmbr servings / wk ( n = nmbr ),characteristic_name
608,peri - op amiodarone : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op amiodarone : no ( n = nmbr ),characteristic_level
609,left atrial diameter : < nmbr mm ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,left atrial diameter : < nmbr mm ( n = nmbr ),characteristic_level
610,"peri - op beta - blockers : no ( n = nmbr ) """,characteristic_name;characteristic_level,characteristic_level,"peri - op beta - blockers : no ( n = nmbr ) """,characteristic_level
611,ejection fraction : < nmbr % ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,ejection fraction : < nmbr % ( n = nmbr ),characteristic_name
612,peri - op statins : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op statins : no ( n = nmbr ),characteristic_level
613,overall ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,overall ( n = nmbr ),characteristic_level
614,nyha class nmbr - nmbr : no { n = llll ),characteristic_name;characteristic_level,characteristic_level,nyha class nmbr - nmbr : no { n = llll ),characteristic_level
615,peri - op beta - blockers : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op beta - blockers : no ( n = nmbr ),characteristic_level
616,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),characteristic_level
617,cross - damp time : < l : llhrs : min ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,cross - damp time : < l : llhrs : min ( n = nmbr ),characteristic_name
618,on - pump time : < l : nmbrhrs : min ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,on - pump time : < l : nmbrhrs : min ( n = nmbr ),characteristic_name
619,sex : male ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,sex : male ( n = nmbr ),characteristic_name
620,country : argentina ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,country : argentina ( n = nmbr ),characteristic_name
621,age : < nmbr years ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,age : < nmbr years ( n = nmbr ),characteristic_level
622,hypertension : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,hypertension : no ( n = nmbr ),characteristic_level
623,cardiac valve surgery : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,cardiac valve surgery : no ( n = nmbr ),characteristic_level
624,study drug loading days ( actual ) : nmbr ( n = nmbr ),characteristic_name;characteristic_level,other,study drug loading days ( actual ) : nmbr ( n = nmbr ),other
625,peri - op ace - inhibitors / arbs : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op ace - inhibitors / arbs : no ( n = nmbr ),characteristic_level
626,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),characteristic_level
628,( nmbr % cl ) interaction,arms;p-interaction,measures,( nmbr % cl ) interaction,measures
629,n - nmbr pufa,arms;p-interaction,arms,n - nmbr pufa,arms
631,% change median baseline crp > nmbrmg / l,characteristic_name;measures,measures,% change median baseline crp > nmbrmg / l,measures
632,"baseline crp < nmbrmg / l """,characteristic_name;measures,characteristic_name,"baseline crp < nmbrmg / l """,characteristic_name
633,baseline crp < nmbrmg / l,characteristic_name;measures,characteristic_name,baseline crp < nmbrmg / l,characteristic_name
634,change from baseline,other;measures,measures,change from baseline,measures
635,baseline,other;measures,characteristic_name,baseline,characteristic_name
636,week nmbr,other;measures,measures,week nmbr,measures
637,"baseline """,other;measures,characteristic_name,"baseline """,characteristic_name
638,fibrinolysis ( n = nmbr ),arms;other,characteristic_level,fibrinolysis ( n = nmbr ),characteristic_level
639,p valuey,arms;other,characteristic_name,p valuey,characteristic_name
640,"p valuey """,arms;other,characteristic_name,"p valuey """,characteristic_name
641,primary pci ( n = nmbr ),arms;other,outcomes,primary pci ( n = nmbr ),outcomes
642,p value,arms;measures;other;p-interaction,measures,p value,measures
643,"fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ) """,arms;measures;other;p-interaction,characteristic_level,"fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ) """,characteristic_level
644,p value for interaction,arms;measures;other;p-interaction,measures,p value for interaction,measures
645,relative risk ( nmbr % ci ) ofprimary end point,arms;measures;other;p-interaction,measures,relative risk ( nmbr % ci ) ofprimary end point,measures
646,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),arms;measures;other;p-interaction,characteristic_level,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),characteristic_level
647,control ( n = nmbr ),arms;other,arms,control ( n = nmbr ),arms
648,watchman ( n = nmbr ),arms;other,characteristic_level,watchman ( n = nmbr ),characteristic_level
649,"p value """,arms;other,measures,"p value """,measures
650,p value,arms;other,measures,p value,measures
651,all,characteristic_name;measures,outcomes,all,outcomes
652,p,characteristic_name;measures,characteristic_name,p,characteristic_name
653,"p """,characteristic_name;measures,characteristic_name,"p """,characteristic_name
654,diabetes,characteristic_name;measures,characteristic_level,diabetes,characteristic_level
655,no diabetes,characteristic_name;measures,characteristic_level,no diabetes,characteristic_level
656,p value *,arms;measures,measures,p value *,measures
657,control ( n - nmbr ),arms;measures,arms,control ( n - nmbr ),arms
658,statin ( n - nmbr ),arms;measures,arms,statin ( n - nmbr ),arms
659,"control ( n - nmbr ) """,arms;measures,arms,"control ( n - nmbr ) """,arms
660,orc ( nmbr % cl ),arms;measures;p-interaction,measures,orc ( nmbr % cl ),measures
661,p value,arms;measures;p-interaction,measures,p value,measures
662,oradj ( nmbr % cl ),arms;measures;p-interaction,measures,oradj ( nmbr % cl ),measures
663,p for interaction,arms;measures;p-interaction,characteristic_name,p for interaction,characteristic_name
664,events / control group,arms;measures;p-interaction,arms,events / control group,arms
665,events / statin group,arms;measures;p-interaction,measures,events / statin group,measures
666,"events / control group """,arms;measures;p-interaction,arms,"events / control group """,arms
667,or [nmbr % ci],arms;measures;p-interaction,other,or [nmbr % ci],other
668,ipst,arms;measures;p-interaction,characteristic_name,ipst,characteristic_name
669,no ipst,arms;measures;p-interaction,characteristic_level,no ipst,characteristic_level
670,"ipst """,arms;measures;p-interaction,characteristic_name,"ipst """,characteristic_name
671,p [int],arms;measures;p-interaction,characteristic_name,p [int],characteristic_name
672,"ff nmbr gg ( n = nmbr , nmbr ) """,arms;measures,arms,"ff nmbr gg ( n = nmbr , nmbr ) """,arms
673,"ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )",arms;measures,arms,"ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )",arms
674,"ff nmbr gg ( n = nmbr , nmbr )",arms;measures,arms,"ff nmbr gg ( n = nmbr , nmbr )",arms
675,"total ( n = nmbr , nmbr )",arms;measures,characteristic_level,"total ( n = nmbr , nmbr )",characteristic_level
676,"total ( n = nmbr ) """,arms;measures,arms,"total ( n = nmbr ) """,arms
678,total ( n = nmbr ),arms;measures,arms,total ( n = nmbr ),arms
679,indacaterol nmbr ug ( n = nmbr ),arms;measures,arms,indacaterol nmbr ug ( n = nmbr ),arms
680,sex : female,characteristic_name;characteristic_level,characteristic_name,sex : female,characteristic_name
681,sex : male,characteristic_name;characteristic_level,characteristic_name,sex : male,characteristic_name
682,overall,characteristic_name;characteristic_level,characteristic_level,overall,characteristic_level
683,ics use at baseline : no,characteristic_name;characteristic_level,characteristic_name,ics use at baseline : no,characteristic_name
684,bmi : > nmbr . nmbr kg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi : > nmbr . nmbr kg / mnmbr,characteristic_level
685,moderate or less airflow limitation,characteristic_name;characteristic_level,characteristic_level,moderate or less airflow limitation,characteristic_level
686,age : < nmbr years,characteristic_name;characteristic_level,characteristic_level,age : < nmbr years,characteristic_level
687,smoking : current smoker,characteristic_name;characteristic_level,characteristic_level,smoking : current smoker,characteristic_level
688,ics use at baseline : yes,characteristic_name;characteristic_level,characteristic_name,ics use at baseline : yes,characteristic_name
689,age : > nmbr years,characteristic_name;characteristic_level,characteristic_level,age : > nmbr years,characteristic_level
690,bmi : < nmbr . nmbr kg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi : < nmbr . nmbr kg / mnmbr,characteristic_level
691,smoking : ex - smoker,characteristic_name;characteristic_level,characteristic_name,smoking : ex - smoker,characteristic_name
692,reversibility : < nmbr %,characteristic_name;characteristic_level,characteristic_level,reversibility : < nmbr %,characteristic_level
693,reversibility : > nmbr - < nmbr %,characteristic_name;characteristic_level,characteristic_level,reversibility : > nmbr - < nmbr %,characteristic_level
694,"sex : male """,characteristic_name;characteristic_level,characteristic_name,"sex : male """,characteristic_name
695,reversibility : > nmbr %,characteristic_name;characteristic_level,characteristic_level,reversibility : > nmbr %,characteristic_level
696,severe or worse airflow limitation,characteristic_name;characteristic_level,characteristic_level,severe or worse airflow limitation,characteristic_level
697,male,characteristic_level;characteristic_name,characteristic_level,male,characteristic_level
698,bl updrs : high,characteristic_level;characteristic_name,characteristic_level,bl updrs : high,characteristic_level
699,bl updrs : low,characteristic_level;characteristic_name,characteristic_name,bl updrs : low,characteristic_name
700,bl h / y : unilateral,characteristic_level;characteristic_name,characteristic_name,bl h / y : unilateral,characteristic_name
701,bl h / y : bilateral,characteristic_level;characteristic_name,characteristic_name,bl h / y : bilateral,characteristic_name
702,age < nmbryrs,characteristic_level;characteristic_name,characteristic_name,age < nmbryrs,characteristic_name
703,"bl updrs : low """,characteristic_level;characteristic_name,characteristic_name,"bl updrs : low """,characteristic_name
704,female,characteristic_level;characteristic_name,characteristic_level,female,characteristic_level
705,age nmbr + yrs,characteristic_level;characteristic_name,characteristic_level,age nmbr + yrs,characteristic_level
706,"nmbrmg vs placebo """,measures;p-interaction,arms,"nmbrmg vs placebo """,arms
707,p - value ( lnteraction ),measures;p-interaction,measures,p - value ( lnteraction ),measures
708,nmbrmg vs placebo,measures;p-interaction,arms,nmbrmg vs placebo,arms
709,hbalc > median,characteristic_name;characteristic_level,characteristic_level,hbalc > median,characteristic_level
710,omega - nmbr fatty acid,characteristic_name;characteristic_level,arms,omega - nmbr fatty acid,arms
711,age < nmbr years,characteristic_name;characteristic_level,characteristic_level,age < nmbr years,characteristic_level
712,placebo,characteristic_name;characteristic_level,arms,placebo,arms
713,men,characteristic_name;characteristic_level,characteristic_level,men,characteristic_level
714,age > nmbr years,characteristic_name;characteristic_level,characteristic_level,age > nmbr years,characteristic_level
716,women,characteristic_name;characteristic_level,characteristic_level,women,characteristic_level
717,"education > nmbr years """,characteristic_name;characteristic_level,characteristic_level,"education > nmbr years """,characteristic_level
718,education nmbr - nmbr years,characteristic_name;characteristic_level,characteristic_level,education nmbr - nmbr years,characteristic_level
719,no diabetes,characteristic_name;characteristic_level,characteristic_level,no diabetes,characteristic_level
720,hbak > median,characteristic_name;characteristic_level,characteristic_level,hbak > median,characteristic_level
721,depression,characteristic_name;characteristic_level,characteristic_name,depression,characteristic_name
722,no depression,characteristic_name;characteristic_level,characteristic_level,no depression,characteristic_level
723,education > nmbr years,characteristic_name;characteristic_level,characteristic_level,education > nmbr years,characteristic_level
724,diabetes,characteristic_name;characteristic_level,characteristic_level,diabetes,characteristic_level
725,hbak < median,characteristic_name;characteristic_level,characteristic_level,hbak < median,characteristic_level
726,education < nmbr years,characteristic_name;characteristic_level,characteristic_level,education < nmbr years,characteristic_level
727,hba < median,characteristic_name;characteristic_level,characteristic_level,hba < median,characteristic_level
728,"number standard care """,p-interaction;measures,arms,"number standard care """,arms
729,number standard care,p-interaction;measures,arms,number standard care,arms
730,p nmbr interaction,p-interaction;measures,characteristic_name,p nmbr interaction,characteristic_name
731,insulin glargine vs standard care least - squares mean ( nmbr % cl ),p-interaction;measures,arms,insulin glargine vs standard care least - squares mean ( nmbr % cl ),arms
732,number insulin glargine,p-interaction;measures,arms,number insulin glargine,arms
735,hbalc < median,characteristic_name;characteristic_level,characteristic_level,hbalc < median,characteristic_level
739,insulin glargine,characteristic_name;characteristic_level,arms,insulin glargine,arms
741,standard care,characteristic_name;characteristic_level,arms,standard care,arms
750,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),measures;p-interaction,arms,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),arms
751,number omega - nmbr number placeb fatty acid,measures;p-interaction,characteristic_name,number omega - nmbr number placeb fatty acid,characteristic_name
752,"number omega - nmbr number placeb fatty acid """,measures;p-interaction,characteristic_name,"number omega - nmbr number placeb fatty acid """,characteristic_name
753,p . interaction,measures;p-interaction,characteristic_name,p . interaction,characteristic_name
754,male,characteristic_name;characteristic_level,characteristic_level,male,characteristic_level
755,bmi < nmbrkg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi < nmbrkg / mnmbr,characteristic_level
756,with beta blocker,characteristic_name;characteristic_level,characteristic_level,with beta blocker,characteristic_level
757,all patients,characteristic_name;characteristic_level,characteristic_level,all patients,characteristic_level
758,fbs < nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level,fbs < nmbr mg / dl,characteristic_level
759,with acei / arb,characteristic_name;characteristic_level,arms,with acei / arb,arms
760,family history of diabetes ( - ),characteristic_name;characteristic_level,characteristic_name,family history of diabetes ( - ),characteristic_name
761,family history of diabetes ( + ),characteristic_name;characteristic_level,characteristic_name,family history of diabetes ( + ),characteristic_name
762,without beta blocker,characteristic_name;characteristic_level,characteristic_level,without beta blocker,characteristic_level
763,without acei / arb,characteristic_name;characteristic_level,characteristic_level,without acei / arb,characteristic_level
764,"age > = nmbr years old """,characteristic_name;characteristic_level,characteristic_level,"age > = nmbr years old """,characteristic_level
765,bmi > = nmbrkg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi > = nmbrkg / mnmbr,characteristic_level
767,age < nmbr years old,characteristic_name;characteristic_level,characteristic_level,age < nmbr years old,characteristic_level
768,fbs > = nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level,fbs > = nmbr mg / dl,characteristic_level
769,age > = nmbr years old,characteristic_name;characteristic_level,characteristic_level,age > = nmbr years old,characteristic_level
770,number ( % ),measures;p-interaction,characteristic_name,number ( % ),characteristic_name
771,p : interaction,measures;p-interaction,characteristic_name,p : interaction,characteristic_name
772,"number ( % ) """,measures;p-interaction,characteristic_name,"number ( % ) """,characteristic_name
773,unadjusted hr,measures;p-interaction,measures,unadjusted hr,measures
774,continuation,arms;measures;p-interaction,characteristic_name,continuation,characteristic_name
776,"relative risk ( nmbr % cl ) """,arms;measures;p-interaction,measures,"relative risk ( nmbr % cl ) """,measures
777,relative risk ( nmbr % cl ),arms;measures;p-interaction,measures,relative risk ( nmbr % cl ),measures
778,interruption,arms;measures;p-interaction,characteristic_name,interruption,characteristic_name
780,"interruption """,arms;measures;p-interaction,characteristic_name,"interruption """,characteristic_name
784,endpoint rate,measures;p-interaction,measures,endpoint rate,measures
785,p - value ( int ),measures;p-interaction,measures,p - value ( int ),measures
786,"endpoint rate """,measures;p-interaction,measures,"endpoint rate """,measures
787,hazard ratio ( nmbr % cl ),measures;arms;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
788,"hazard ratio ( nmbr % cl ) """,measures;arms;p-interaction,measures,"hazard ratio ( nmbr % cl ) """,measures
789,interact !,measures;arms;p-interaction,characteristic_name,interact !,characteristic_name
790,sal nmbr pg ( n = nmbr ),arms;measures,arms,sal nmbr pg ( n = nmbr ),arms
792,"sal nmbr pg ( n = nmbr ) """,arms;measures,arms,"sal nmbr pg ( n = nmbr ) """,arms
793,fp / sal nmbr / nmbr pg ( n = nmbr ),arms;measures,arms,fp / sal nmbr / nmbr pg ( n = nmbr ),arms
794,"total n = nmbr """,arms;measures,arms,"total n = nmbr """,arms
795,saxa + dapa + met n = nmbr,arms;measures,arms,saxa + dapa + met n = nmbr,arms
796,dapa + met n = nmbr,arms;measures,arms,dapa + met n = nmbr,arms
797,saxa + met n = nmbr,arms;measures,arms,saxa + met n = nmbr,arms
798,total n = nmbr,arms;measures,arms,total n = nmbr,arms
799,warfarin group,arms;other,arms,warfarin group,arms
800,"device group """,arms;other,arms,"device group """,arms
801,device group,arms;other,arms,device group,arms
802,hr ( nmbr % ci ),arms;other,measures,hr ( nmbr % ci ),measures
803,hrnmbr and nmbr % cl,measures;arms;p-interaction;other,measures,hrnmbr and nmbr % cl,measures
804,p value for interaction,measures;arms;p-interaction;other,measures,p value for interaction,measures
805,placebo n ( % ),measures;arms;p-interaction;other,arms,placebo n ( % ),arms
806,"continued thienopyridine n ( % ) """,measures;arms;p-interaction;other,arms,"continued thienopyridine n ( % ) """,arms
807,continued thienopyridine n ( % ),measures;arms;p-interaction;other,arms,continued thienopyridine n ( % ),arms
808,n,measures;arms;p-interaction;other,characteristic_name,n,characteristic_name
809,"placebo ( n = nmbr , nmbr )",arms;p-interaction,arms,"placebo ( n = nmbr , nmbr )",arms
810,"placebo ( n = nmbr , nmbr ) """,arms;p-interaction,arms,"placebo ( n = nmbr , nmbr ) """,arms
811,"vorapaxar ( n = nmbr , nmbr )",arms;p-interaction,arms,"vorapaxar ( n = nmbr , nmbr )",arms
813,women > nmbr years,characteristic_name;characteristic_level,characteristic_level,women > nmbr years,characteristic_level
814,total study population,characteristic_name;characteristic_level,other,total study population,other
815,"total study population """,characteristic_name;characteristic_level,other,"total study population """,other
816,women < nmbr years,characteristic_name;characteristic_level,characteristic_level,women < nmbr years,characteristic_level
817,"placebo ( n = nmbr , nmbr )",arms;measures;p-interaction,arms,"placebo ( n = nmbr , nmbr )",arms
818,placebo ( n = nmbr ),arms;measures;p-interaction,arms,placebo ( n = nmbr ),arms
819,p,arms;measures;p-interaction,characteristic_name,p,characteristic_name
820,p for interaction *,arms;measures;p-interaction,characteristic_name,p for interaction *,characteristic_name
821,saxagliptin nmbr . nmbr mg ( n = nmbr ),arms;measures;p-interaction,arms,saxagliptin nmbr . nmbr mg ( n = nmbr ),arms
822,hr ( nmbr % ci ),arms;measures;p-interaction,measures,hr ( nmbr % ci ),measures
823,"hr ( nmbr % ci ) """,arms;measures;p-interaction,measures,"hr ( nmbr % ci ) """,measures
824,"saxagliptin nmbr mg ( n = nmbr , nmbr )",arms;measures;p-interaction,arms,"saxagliptin nmbr mg ( n = nmbr , nmbr )",arms
825,"saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )",arms;measures;p-interaction,arms,"saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )",arms
826,p - value for interaction,measures;p-interaction,measures,p - value for interaction,measures
827,hr ( nmbr % cl ),measures;p-interaction,measures,hr ( nmbr % cl ),measures
828,"hr ( nmbr % cl ) """,measures;p-interaction,measures,"hr ( nmbr % cl ) """,measures
829,nmbr yr km % ( n ),measures;p-interaction,characteristic_level,nmbr yr km % ( n ),characteristic_level
831,"no dm ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"no dm ( n = nmbr ) """,characteristic_level
832,dm ( n = nmbr ),characteristic_level;measures,characteristic_name,dm ( n = nmbr ),characteristic_name
833,no dm ( n = nmbr ),characteristic_level;measures,characteristic_level,no dm ( n = nmbr ),characteristic_level
834,p value,measures;p-interaction;arms,measures,p value,measures
835,hr ( nmbr % ci ),measures;p-interaction;arms,measures,hr ( nmbr % ci ),measures
836,"vorapaxar event rate ( n = nmbr ) , %",measures;p-interaction;arms,measures,"vorapaxar event rate ( n = nmbr ) , %",measures
837,p value ( int ),measures;p-interaction;arms,measures,p value ( int ),measures
838,"vorapaxar event rate ( n = nmbr ) , % """,measures;p-interaction;arms,measures,"vorapaxar event rate ( n = nmbr ) , % """,measures
839,"placebo event rate ( n = nmbr ) , %",measures;p-interaction;arms,measures,"placebo event rate ( n = nmbr ) , %",measures
840,"hr """,measures;p-interaction,measures,"hr """,measures
842,hr,measures;p-interaction,measures,hr,measures
843,nmbr % cl,measures;p-interaction,measures,nmbr % cl,measures
844,nmbr % ci,measures;p-interaction,measures,nmbr % ci,measures
849,saxagliptin,arms;measures,arms,saxagliptin,arms
850,"saxagliptin """,arms;measures,arms,"saxagliptin """,arms
851,vorapaxar placebo nmbr - yr . km % rate,arms;measures;p-interaction,arms,vorapaxar placebo nmbr - yr . km % rate,arms
852,total no .,arms;measures;p-interaction,measures,total no .,measures
858,p vs placebo,arms;measures,arms,p vs placebo,arms
859,nnmbr / nnmbr,measures;arms,characteristic_name,nnmbr / nnmbr,characteristic_name
860,lsm ( nmbr % cl ),measures;arms,measures,lsm ( nmbr % cl ),measures
861,"nnmbr / nnmbr """,measures;arms,characteristic_name,"nnmbr / nnmbr """,characteristic_name
862,placebo mean ( n ),arms;measures,arms,placebo mean ( n ),arms
863,liraglutide nmbr . nmbr mg mean ( n ),arms;measures,arms,liraglutide nmbr . nmbr mg mean ( n ),arms
864,"estimated difference """,arms;measures,measures,"estimated difference """,measures
865,estimated difference,arms;measures,measures,estimated difference,measures
866,warfarin,arms;measures,arms,warfarin,arms
867,p for i,arms;measures,characteristic_name,p for i,characteristic_name
868,"p for i """,arms;measures,characteristic_name,"p for i """,characteristic_name
869,hr nmbr % cl,arms;measures,measures,hr nmbr % cl,measures
872,apixaban,arms;measures,arms,apixaban,arms
873,apixaban vs . placebo,arms;measures,arms,apixaban vs . placebo,arms
875,control,arms;measures;p-interaction,arms,control,arms
876,p - value for interaction nmbr . nmbr,arms;measures;p-interaction,measures,p - value for interaction nmbr . nmbr,measures
877,"p - value for interaction nmbr . nmbr """,arms;measures;p-interaction,measures,"p - value for interaction nmbr . nmbr """,measures
878,odds ratio ( nmbr % cl ),arms;measures;p-interaction,measures,odds ratio ( nmbr % cl ),measures
879,cyclo,arms;measures;p-interaction,characteristic_name,cyclo,characteristic_name
880,tp vs no tp,characteristic_level;p-interaction,measures,tp vs no tp,measures
881,"no thienopyridine """,characteristic_level;p-interaction,characteristic_level,"no thienopyridine """,characteristic_level
882,thienopyridine,characteristic_level;p-interaction,arms,thienopyridine,arms
883,no thienopyridine,characteristic_level;p-interaction,characteristic_level,no thienopyridine,characteristic_level
884,all n = nmbr nmbr,measures;arms,characteristic_level,all n = nmbr nmbr,characteristic_level
885,vorapaxar n = nmbr,measures;arms,arms,vorapaxar n = nmbr,arms
886,"vorapaxar n = nmbr """,measures;arms,arms,"vorapaxar n = nmbr """,arms
887,placebo n = nmbr,measures;arms,arms,placebo n = nmbr,arms
888,all n = nmbr,measures;arms,characteristic_level,all n = nmbr,characteristic_level
889,mrf subjects,characteristic_level;characteristic_name,arms,mrf subjects,arms
890,"sex , female",characteristic_level;characteristic_name,characteristic_name,"sex , female",characteristic_name
891,"renal function , moderate",characteristic_level;characteristic_name,characteristic_name,"renal function , moderate",characteristic_name
892,age > = nmbr,characteristic_level;characteristic_name,characteristic_name,age > = nmbr,characteristic_name
893,"sex , male",characteristic_level;characteristic_name,characteristic_name,"sex , male",characteristic_name
894,"renal function , moderate """,characteristic_level;characteristic_name,characteristic_name,"renal function , moderate """,characteristic_name
895,"region , latin america",characteristic_level;characteristic_name,characteristic_name,"region , latin america",characteristic_name
896,"region , europe",characteristic_level;characteristic_name,characteristic_name,"region , europe",characteristic_name
897,"race , while",characteristic_level;characteristic_name,characteristic_name,"race , while",characteristic_name
898,age < nmbr,characteristic_level;characteristic_name,characteristic_name,age < nmbr,characteristic_name
899,"region , north america",characteristic_level;characteristic_name,characteristic_name,"region , north america",characteristic_name
900,"region , asia / paafic",characteristic_level;characteristic_name,characteristic_name,"region , asia / paafic",characteristic_name
901,"renal function , severe",characteristic_level;characteristic_name,characteristic_name,"renal function , severe",characteristic_name
902,cvd subjects,characteristic_level;characteristic_name,arms,cvd subjects,arms
903,oretal,characteristic_level;characteristic_name,characteristic_name,oretal,characteristic_name
904,"race , non - white",characteristic_level;characteristic_name,characteristic_level,"race , non - white",characteristic_level
905,"renal function , normal - mild",characteristic_level;characteristic_name,characteristic_name,"renal function , normal - mild",characteristic_name
906,"region , europe union",characteristic_level;characteristic_name,characteristic_name,"region , europe union",characteristic_name
907,hazard ratio,measures;p-interaction,measures,hazard ratio,measures
909,"hazard ratio """,measures;p-interaction,measures,"hazard ratio """,measures
910,( nmbr % ci ),measures;p-interaction,measures,( nmbr % ci ),measures
914,patients with event / patients analyzed,measures;p-interaction,characteristic_level,patients with event / patients analyzed,characteristic_level
916,cangrelor,arms;measures;p-interaction,arms,cangrelor,arms
917,clopidogrel,arms;measures;p-interaction,arms,clopidogrel,arms
918,"or ( nmbr % cl ) """,arms;measures;p-interaction,measures,"or ( nmbr % cl ) """,measures
919,or ( nmbr % cl ),arms;measures;p-interaction,measures,or ( nmbr % cl ),measures
920,p interaction,arms;measures;p-interaction,characteristic_name,p interaction,characteristic_name
921,"brv nmbr mg / day ( n = nmbr ) """,arms;measures,arms,"brv nmbr mg / day ( n = nmbr ) """,arms
922,brv nmbr mg / day ( n = nmbr ),arms;measures,arms,brv nmbr mg / day ( n = nmbr ),arms
923,pbo ( n = nmbr ),arms;measures,arms,pbo ( n = nmbr ),arms
924,"outcome """,arms;outcomes;measures;p-interaction,outcomes,"outcome """,outcomes
925,p interaction,arms;outcomes;measures;p-interaction,characteristic_name,p interaction,characteristic_name
926,hr ( nmbr % cl ),arms;outcomes;measures;p-interaction,measures,hr ( nmbr % cl ),measures
927,outcome,arms;outcomes;measures;p-interaction,outcomes,outcome,outcomes
928,saxagliptin ( % ),arms;measures;p-interaction,arms,saxagliptin ( % ),arms
929,placebo ( % ),arms;measures;p-interaction,arms,placebo ( % ),arms
932,"saxagliptin ( % ) """,arms;measures;p-interaction,arms,"saxagliptin ( % ) """,arms
938,"placebo % """,arms;measures;p-interaction,arms,"placebo % """,arms
939,p value for interactiont,arms;measures;p-interaction,measures,p value for interactiont,measures
940,continued thienopyridine %,arms;measures;p-interaction,arms,continued thienopyridine %,arms
942,placebo %,arms;measures;p-interaction,arms,placebo %,arms
943,n,arms;measures;p-interaction,characteristic_name,n,characteristic_name
944,treatment arm,arms;measures,characteristic_name,treatment arm,characteristic_name
945,pvalue,arms;measures,measures,pvalue,measures
946,"treatment arm """,arms;measures,characteristic_name,"treatment arm """,characteristic_name
947,warfarin,arms;measures;p-interaction,arms,warfarin,arms
949,laa closure,arms;measures;p-interaction,characteristic_name,laa closure,characteristic_name
950,"hazard ratio ( nmbr % confi dence interval ) """,arms;measures;p-interaction,measures,"hazard ratio ( nmbr % confi dence interval ) """,measures
951,hazard ratio ( nmbr % confi dence interval ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % confi dence interval ),measures
954,"subgroup """,arms;measures,characteristic_level,"subgroup """,characteristic_level
956,stent ( n = nmbr ),arms;measures,arms,stent ( n = nmbr ),arms
957,subgroup,arms;measures,characteristic_level,subgroup,characteristic_level
958,medical therapy ( n = nmbr ),arms;measures,characteristic_name,medical therapy ( n = nmbr ),characteristic_name
959,value,arms;measures,measures,value,measures
961,hazard ratio ( nmbr % cl ),arms;measures,measures,hazard ratio ( nmbr % cl ),measures
962,"value """,arms;measures,measures,"value """,measures
963,medical therapy,arms;measures,characteristic_name,medical therapy,characteristic_name
964,stent,arms;measures,characteristic_name,stent,characteristic_name
965,hazard ratio,arms;measures;p-interaction,measures,hazard ratio,measures
966,standard care n ( % ),arms;measures;p-interaction,arms,standard care n ( % ),arms
967,insulin glargine n ( x ),arms;measures;p-interaction,arms,insulin glargine n ( x ),arms
968,"standard care n ( % ) """,arms;measures;p-interaction,arms,"standard care n ( % ) """,arms
970,nmbr % cl,arms;measures;p-interaction,measures,nmbr % cl,measures
973,"selexipag ( n = nmbr ) """,arms;measures,arms,"selexipag ( n = nmbr ) """,arms
974,selexipag ( n = nmbr ),arms;measures,arms,selexipag ( n = nmbr ),arms
975,change from baseline ( % ),measures;p-interaction,measures,change from baseline ( % ),measures
976,"change from baseline ( % ) """,measures;p-interaction,measures,"change from baseline ( % ) """,measures
977,etd ( % ) [nmbr % ci],arms;p-interaction,measures,etd ( % ) [nmbr % ci],measures
978,liraglutide nmbr . nmbr mg ls means ( n ),arms;p-interaction,arms,liraglutide nmbr . nmbr mg ls means ( n ),arms
979,"placebo ls means ( n ) """,arms;p-interaction,arms,"placebo ls means ( n ) """,arms
980,placebo ls means ( n ),arms;p-interaction,arms,placebo ls means ( n ),arms
981,"ratio of hrs ( nmbr % ci ) , p for sex interaction",measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % ci ) , p for sex interaction",characteristic_name
982,no of events women men *,measures;p-interaction,characteristic_level,no of events women men *,characteristic_level
983,"ratio of hrs ( nmbr % ci ) , p for sex interaction """,measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % ci ) , p for sex interaction """,characteristic_name
984,"ratio of hrs ( nmbr % cl ) , p for sex interaction """,measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % cl ) , p for sex interaction """,characteristic_name
985,no of events womenmen *,measures;p-interaction,measures,no of events womenmen *,measures
986,"ratio of hrs ( nmbr % cl ) , p for sex interaction",measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % cl ) , p for sex interaction",characteristic_name
987,women ( n = nmbr ),characteristic_level;measures,characteristic_level,women ( n = nmbr ),characteristic_level
988,"men ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"men ( n = nmbr ) """,characteristic_level
989,p value ( cangrelor versus clopidogrel in women ),characteristic_level;measures,arms,p value ( cangrelor versus clopidogrel in women ),arms
990,p value ( cangrelor versus clopidogrel in men ),characteristic_level;measures,arms,p value ( cangrelor versus clopidogrel in men ),arms
991,p value ( men versus women ),characteristic_level;measures,characteristic_level,p value ( men versus women ),characteristic_level
992,men ( n = nmbr ),characteristic_level;measures,characteristic_level,men ( n = nmbr ),characteristic_level
993,"total no . """,measures;p-interaction,measures,"total no . """,measures
994,"events , no .",measures;p-interaction,measures,"events , no .",measures
995,total no .,measures;p-interaction,measures,total no .,measures
997,"nmbr - wk kaplan - meier rate , %",measures;p-interaction,measures,"nmbr - wk kaplan - meier rate , %",measures
998,hazard ratio ( nmbr % cl ),measures;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
999,"no mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"no mi ( n - nmbr , nmbr )",characteristic_level
1000,"index mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"index mi ( n - nmbr , nmbr )",characteristic_level
1001,"prior mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"prior mi ( n - nmbr , nmbr )",characteristic_level
1002,"any mi ( n - nmbr , nmbr ) """,characteristic_level;measures,characteristic_level,"any mi ( n - nmbr , nmbr ) """,characteristic_level
1003,pvaluefor any mi versus no mi,characteristic_level;measures,characteristic_level,pvaluefor any mi versus no mi,characteristic_level
1004,"any mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"any mi ( n - nmbr , nmbr )",characteristic_level
1005,"diabetes ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"diabetes ( n - nmbr , nmbr )",characteristic_level
1006,"no diabetes ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"no diabetes ( n - nmbr , nmbr )",characteristic_level
1007,"diabetes ( n - nmbr , nmbr ) """,characteristic_level;measures,characteristic_level,"diabetes ( n - nmbr , nmbr ) """,characteristic_level
1010,"no pad ( n - nmbr , nmbr )",arms;measures,characteristic_level,"no pad ( n - nmbr , nmbr )",characteristic_level
1011,"pad ( n - nmbr , nmbr ) """,arms;measures,characteristic_level,"pad ( n - nmbr , nmbr ) """,characteristic_level
1012,"pad ( n - nmbr , nmbr )",arms;measures,characteristic_level,"pad ( n - nmbr , nmbr )",characteristic_level
1013,rosuvastatin,arms;measures,arms,rosuvastatin,arms
1015,trend / het . test,arms;measures,characteristic_name,trend / het . test,characteristic_name
1016,odds ratio ( nmbr % cl ),arms;measures,measures,odds ratio ( nmbr % cl ),measures
1017,"odds ratio ( nmbr % cl ) """,arms;measures,measures,"odds ratio ( nmbr % cl ) """,measures
1019,percentage difference ( nmbr % cl ),arms;measures,measures,percentage difference ( nmbr % cl ),measures
1021,heterogeneity test,arms;measures,characteristic_name,heterogeneity test,characteristic_name
1022,"percentage difference ( nmbr % cl ) """,arms;measures,measures,"percentage difference ( nmbr % cl ) """,measures
1028,all patients n = nmbr,arms;measures,characteristic_level,all patients n = nmbr,characteristic_level
1029,"czp + mtx n = nmbr """,arms;measures,arms,"czp + mtx n = nmbr """,arms
1030,czp + mtx n = nmbr,arms;measures,arms,czp + mtx n = nmbr,arms
1031,pbo + mtx n = nmbr,arms;measures,arms,pbo + mtx n = nmbr,arms
1032,salmeterol - fluticasone group,measures;arms,arms,salmeterol - fluticasone group,arms
1033,indacaterol - glycopyrronium group,measures;arms,arms,indacaterol - glycopyrronium group,arms
1034,"indacaterol - glycopyrronium group """,measures;arms,arms,"indacaterol - glycopyrronium group """,arms
1035,rate ratio ( nmbr % cl ),measures;arms,measures,rate ratio ( nmbr % cl ),measures
1036,liraglutide,arms;measures,arms,liraglutide,arms
1037,hazard ratio,arms;measures,measures,hazard ratio,measures
1041,us ( n = nmbr ),arms;measures,characteristic_level,us ( n = nmbr ),characteristic_level
1043,non - us ( n = nmbr ),arms;measures,characteristic_level,non - us ( n = nmbr ),characteristic_level
1045,us ( n = nmbr ),characteristic_level;p-interaction,characteristic_level,us ( n = nmbr ),characteristic_level
1046,"non - us ( n = nmbr ) """,characteristic_level;p-interaction,characteristic_level,"non - us ( n = nmbr ) """,characteristic_level
1047,"p , regional difference",characteristic_level;p-interaction,measures,"p , regional difference",measures
1048,"p , treatment - by - region interaction",characteristic_level;p-interaction,characteristic_name,"p , treatment - by - region interaction",characteristic_name
1049,non - us ( n = nmbr ),characteristic_level;p-interaction,characteristic_level,non - us ( n = nmbr ),characteristic_level
1050,or ( nmbr % ci ),arms;measures,other,or ( nmbr % ci ),other
1051,clopidogrel,arms;measures,arms,clopidogrel,arms
1052,"or ( nmbr % ci ) """,arms;measures,other,"or ( nmbr % ci ) """,other
1053,cangrelor,arms;measures,arms,cangrelor,arms
1054,western europe hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,western europe hr ( nmbr % cl ),measures
1055,central / eastern europe and russia hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,central / eastern europe and russia hr ( nmbr % cl ),measures
1056,north america hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,north america hr ( nmbr % cl ),measures
1057,latin america hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,latin america hr ( nmbr % cl ),measures
1058,pfor interaction,measures;characteristic_level;p-interaction,characteristic_name,pfor interaction,characteristic_name
1059,asia - pacific hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,asia - pacific hr ( nmbr % cl ),measures
1060,"central / eastern europe and russia hr ( nmbr % cl ) """,measures;characteristic_level;p-interaction,measures,"central / eastern europe and russia hr ( nmbr % cl ) """,measures
1061,overall hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,overall hr ( nmbr % cl ),measures
1063,nmbr - nmbr months fn = nmbr . nmbr ),characteristic_level;measures,characteristic_level,nmbr - nmbr months fn = nmbr . nmbr ),characteristic_level
1064,"> nmbr months ( n = nmbr , nmbr )",characteristic_level;measures,characteristic_level,"> nmbr months ( n = nmbr , nmbr )",characteristic_level
1065,< nmbr months in - nmbr kill,characteristic_level;measures,arms,< nmbr months in - nmbr kill,arms
1066,"< nmbr months in - nmbr kill """,characteristic_level;measures,arms,"< nmbr months in - nmbr kill """,arms
1067,"no prior hf hospitalization ( n = nmbr , nmbr )",characteristic_level;measures,characteristic_level,"no prior hf hospitalization ( n = nmbr , nmbr )",characteristic_level
1068,nmbr - nmbr months ( n = nmbr ),characteristic_level;measures,characteristic_level,nmbr - nmbr months ( n = nmbr ),characteristic_level
1069,"event rates , %",measures;p-interaction,measures,"event rates , %",measures
1070,"event rates , % """,measures;p-interaction,measures,"event rates , % """,measures
1071,p - value for variance,measures;p-interaction,measures,p - value for variance,measures
1073,relative risk ( nmbr % ci ),measures;p-interaction,measures,relative risk ( nmbr % ci ),measures
1074,racea white,characteristic_name;characteristic_level,characteristic_level,racea white,characteristic_level
1075,prior congestive heart failure yes,characteristic_name;characteristic_level,characteristic_level,prior congestive heart failure yes,characteristic_level
1076,> median,characteristic_name;characteristic_level,characteristic_level,> median,characteristic_level
1078,asia pacific and other,characteristic_name;characteristic_level,characteristic_level,asia pacific and other,characteristic_level
1079,north america,characteristic_name;characteristic_level,characteristic_level,north america,characteristic_level
1080,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a """,characteristic_name;characteristic_level,characteristic_level,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a """,characteristic_level
1081,body mass indexa < median,characteristic_name;characteristic_level,characteristic_name,body mass indexa < median,characteristic_name
1083,"renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_name;characteristic_level,characteristic_level,"renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_level
1084,"> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_name;characteristic_level,characteristic_level,"> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_level
1086,nyha class > ii,characteristic_name;characteristic_level,characteristic_level,nyha class > ii,characteristic_level
1087,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_name;characteristic_level,characteristic_level,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_level
1088,> nmbr to < nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr to < nmbr,characteristic_level
1089,not hispanic or latino,characteristic_name;characteristic_level,characteristic_level,not hispanic or latino,characteristic_level
1090,prior myocardial infarction yes,characteristic_name;characteristic_level,characteristic_level,prior myocardial infarction yes,characteristic_level
1091,eastern europe,characteristic_name;characteristic_level,characteristic_level,eastern europe,characteristic_level
1093,diabetes durationa < median,characteristic_name;characteristic_level,characteristic_level,diabetes durationa < median,characteristic_level
1094,prior hypertensiona yes,characteristic_name;characteristic_level,characteristic_level,prior hypertensiona yes,characteristic_level
1095,prior coronary artery disease yes,characteristic_name;characteristic_level,characteristic_level,prior coronary artery disease yes,characteristic_level
1096,age < median,characteristic_name;characteristic_level,characteristic_name,age < median,characteristic_name
1097,glycated hemoglobin < median,characteristic_name;characteristic_level,characteristic_name,glycated hemoglobin < median,characteristic_name
1098,nyha class not reported,characteristic_name;characteristic_level,characteristic_name,nyha class not reported,characteristic_name
1099,diuretic thiazide,characteristic_name;characteristic_level,arms,diuretic thiazide,arms
1100,none,characteristic_name;characteristic_level,characteristic_name,none,characteristic_name
1103,angiotensin receptor blocker yes,characteristic_name;characteristic_level,characteristic_level,angiotensin receptor blocker yes,characteristic_level
1104,ace inhibitor yes,characteristic_name;characteristic_level,characteristic_level,ace inhibitor yes,characteristic_level
1106,insulin yes,characteristic_name;characteristic_level,characteristic_level,insulin yes,characteristic_level
1107,baseline heart failure severity nyha class i,characteristic_name;characteristic_level,characteristic_name,baseline heart failure severity nyha class i,characteristic_name
1108,western europe,characteristic_name;characteristic_level,characteristic_level,western europe,characteristic_level
1109,region latin american,characteristic_name;characteristic_level,characteristic_name,region latin american,characteristic_name
1110,ethnicitya hispanic or latino,characteristic_name;characteristic_level,characteristic_level,ethnicitya hispanic or latino,characteristic_level
1111,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_name;characteristic_level,characteristic_level,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_level
1112,p - blocker yes,characteristic_name;characteristic_level,characteristic_level,p - blocker yes,characteristic_level
1113,sexa male,characteristic_name;characteristic_level,characteristic_level,sexa male,characteristic_level
1114,< nmbr,characteristic_name;characteristic_level,characteristic_level,< nmbr,characteristic_level
1115,thiazolidinedione yes,characteristic_name;characteristic_level,characteristic_level,thiazolidinedione yes,characteristic_level
1116,"systolic blood pressure , mm hg < nmbr",characteristic_name;characteristic_level,characteristic_level,"systolic blood pressure , mm hg < nmbr",characteristic_level
1118,p value fo interactio,arms;measures;p-interaction,measures,p value fo interactio,measures
1119,sitagliptin no . / total no .,arms;measures;p-interaction,arms,sitagliptin no . / total no .,arms
1120,"placebo no . / total no . """,arms;measures;p-interaction,arms,"placebo no . / total no . """,arms
1121,placebo no . / total no .,arms;measures;p-interaction,arms,placebo no . / total no .,arms
1122,p - value *,arms;measures,measures,p - value *,measures
1123,placebo events / n ( % ),arms;measures,arms,placebo events / n ( % ),arms
1124,"hr ( nmbr % cl ) """,arms;measures,measures,"hr ( nmbr % cl ) """,measures
1125,pioglitazone events / n ( % ),arms;measures,measures,pioglitazone events / n ( % ),measures
1127,p - interaction,arms;measures;p-interaction,characteristic_name,p - interaction,characteristic_name
1128,ticagrelor nmbr mg nmbr yr km %,arms;measures;p-interaction,arms,ticagrelor nmbr mg nmbr yr km %,arms
1129,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),arms;measures;p-interaction,arms,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),arms
1130,"placebo nmbr yr km % """,arms;measures;p-interaction,arms,"placebo nmbr yr km % """,arms
1131,number of patients,arms;measures;p-interaction,measures,number of patients,measures
1132,placebo nmbr yr km %,arms;measures;p-interaction,arms,placebo nmbr yr km %,arms
1133,p - interactio n,arms;measures;p-interaction,characteristic_name,p - interactio n,characteristic_name
1134,hazard ratio ( nmbr % ci ),arms;p-interaction;measures,measures,hazard ratio ( nmbr % ci ),measures
1135,monitoring treatment,arms;p-interaction;measures,arms,monitoring treatment,arms
1136,conventional treatment,arms;p-interaction;measures,characteristic_name,conventional treatment,characteristic_name
1137,"p interaction """,arms;p-interaction;measures,characteristic_name,"p interaction """,characteristic_name
1138,p interaction,arms;p-interaction;measures,characteristic_name,p interaction,characteristic_name
1140,p - value,arms;measures,measures,p - value,measures
1141,"stent """,arms;measures,characteristic_name,"stent """,characteristic_name
1144,"acs ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"acs ( n - nmbr , nmbr )",characteristic_level
1146,"acs ( n - nmbr , nmbr ) """,characteristic_level;measures,characteristic_level,"acs ( n - nmbr , nmbr ) """,characteristic_level
1147,"stable angina ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"stable angina ( n - nmbr , nmbr )",characteristic_level
1148,statin non - users ( n = nmbr ),arms;measures,characteristic_level,statin non - users ( n = nmbr ),characteristic_level
1150,statin users ( n = nmbr ),arms;measures,arms,statin users ( n = nmbr ),arms
1151,"statin non - users ( n = nmbr ) """,arms;measures,characteristic_level,"statin non - users ( n = nmbr ) """,characteristic_level
1158,peripheral revascularization ( n = nmbr ),arms;measures,characteristic_level,peripheral revascularization ( n = nmbr ),characteristic_level
1159,"no peripheral revascularization ( n = nmbr , nmbr ) """,arms;measures,characteristic_level,"no peripheral revascularization ( n = nmbr , nmbr ) """,characteristic_level
1160,"no peripheral revascularization ( n = nmbr , nmbr )",arms;measures,characteristic_level,"no peripheral revascularization ( n = nmbr , nmbr )",characteristic_level
1162,incidencea,arms;measures,characteristic_name,incidencea,characteristic_name
1165,"patients receiving lcz , no . ( % )",arms;measures,characteristic_level,"patients receiving lcz , no . ( % )",characteristic_level
1166,"patients receiving enl , no . ( % )",arms;measures,characteristic_level,"patients receiving enl , no . ( % )",characteristic_level
1167,adjusted hr ( enl vs lcz ) ( nmbr % cl ),arms;measures,measures,adjusted hr ( enl vs lcz ) ( nmbr % cl ),measures
1168,hr ( enl vs lcz ) ( nmbr % cl ),arms;measures,measures,hr ( enl vs lcz ) ( nmbr % cl ),measures
1170,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),arms;measures,arms,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),arms
1174,placebo pts / n ( % ),arms;measures,arms,placebo pts / n ( % ),arms
1175,pioglitazone pts / n ( % ),arms;measures,characteristic_name,pioglitazone pts / n ( % ),characteristic_name
1176,"pioglitazone pts / n ( % ) """,arms;measures,characteristic_name,"pioglitazone pts / n ( % ) """,characteristic_name
1178,copd - placebo ( n = nmbr ),arms;measures,arms,copd - placebo ( n = nmbr ),arms
1180,"copd - placebo ( n = nmbr ) """,arms;measures,arms,"copd - placebo ( n = nmbr ) """,arms
1181,copd - rosuvastatin ( n = nmbr ),arms;measures,arms,copd - rosuvastatin ( n = nmbr ),arms
1182,copd ( n = nmbr ),arms;measures,characteristic_name,copd ( n = nmbr ),characteristic_name
1183,adjusted,arms;measures,arms,adjusted,arms
1184,unadjusted,arms;measures,characteristic_name,unadjusted,characteristic_name
1185,"adjusted """,arms;measures,arms,"adjusted """,arms
1186,estimated difference ( nmbr % ci ),arms;measures,measures,estimated difference ( nmbr % ci ),measures
1187,abatacept,arms;measures,arms,abatacept,arms
1189,abatacept / open - label abatacept,arms;measures,arms,abatacept / open - label abatacept,arms
1190,placebo / open - label abatacept,arms;measures,arms,placebo / open - label abatacept,arms
1191,"abatacept / open - label abatacept """,arms;measures,arms,"abatacept / open - label abatacept """,arms
1192,hazard ratio ( nmbr % ci ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % ci ),measures
1194,placebo,arms;measures;p-interaction,arms,placebo,arms
1195,canagliflozin,arms;measures;p-interaction,characteristic_name,canagliflozin,characteristic_name
1196,"canagliflozin """,arms;measures;p-interaction,characteristic_name,"canagliflozin """,characteristic_name
1197,linagliptin,arms;measures,arms,linagliptin,arms
1198,treatment difference,arms;measures,measures,treatment difference,measures
1202,"cangrelor , % """,arms;measures;p-interaction,arms,"cangrelor , % """,arms
1203,"cangrelor , %",arms;measures;p-interaction,arms,"cangrelor , %",arms
1204,or ( nmbr % ci ),arms;measures;p-interaction,other,or ( nmbr % ci ),other
1205,"clopidogrel , %",arms;measures;p-interaction,arms,"clopidogrel , %",arms
1206,p value ( int ),arms;measures;p-interaction,measures,p value ( int ),measures
1207,aspirin alone,arms;measures;p-interaction,arms,aspirin alone,arms
1208,rivaroxaban + aspirin,arms;measures;p-interaction,arms,rivaroxaban + aspirin,arms
1210,"rivaroxaban + aspirin """,arms;measures;p-interaction,arms,"rivaroxaban + aspirin """,arms
1211,"hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )",arms;measures;p-interaction,outcomes,"hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )",outcomes
1213,ppci ( n = nmbr ),arms;measures,characteristic_level,ppci ( n = nmbr ),characteristic_level
1215,"ppci ( n = nmbr ) """,arms;measures,characteristic_level,"ppci ( n = nmbr ) """,characteristic_level
1216,phi ( n = nmbr ),arms;measures,characteristic_level,phi ( n = nmbr ),characteristic_level
1217,ppci in - nmbr,arms;measures,arms,ppci in - nmbr,arms
1218,phi ( n - nmbr ),arms;measures,characteristic_level,phi ( n - nmbr ),characteristic_level
1219,"( nmbr % cl ) """,arms;measures,measures,"( nmbr % cl ) """,measures
1220,( nmbr % cl ),arms;measures,measures,( nmbr % cl ),measures
1221,rr,arms;measures,characteristic_name,rr,characteristic_name
1223,rate ratio,arms;measures;p-interaction,measures,rate ratio,measures
1224,hdl - c,arms;measures;p-interaction,characteristic_name,hdl - c,characteristic_name
1225,non - hdl - c,arms;measures;p-interaction,outcomes,non - hdl - c,outcomes
1226,p - value interaction,arms;measures;p-interaction,measures,p - value interaction,measures
1227,anacetrapib ( n = nmbr ),arms;measures;p-interaction,arms,anacetrapib ( n = nmbr ),arms
1228,"non - hdl - c """,arms;measures;p-interaction,outcomes,"non - hdl - c """,outcomes
1229,"month nmbr """,measures;other,characteristic_name,"month nmbr """,characteristic_name
1230,monthnmbr,measures;other,characteristic_name,monthnmbr,characteristic_name
1231,month nmbr,measures;other,characteristic_name,month nmbr,characteristic_name
1232,baseline,measures;other,characteristic_name,baseline,characteristic_name
1233,p values,arms;measures,characteristic_name,p values,characteristic_name
1234,tiotropium,arms;measures,arms,tiotropium,arms
1237,difference ( tiotropium - placebo ) ml ( nmbr % ci ),arms;measures,measures,difference ( tiotropium - placebo ) ml ( nmbr % ci ),measures
1238,mepolizumab group,measures;arms,arms,mepolizumab group,arms
1239,"rate ratio ( nmbr % cl ) """,measures;arms,measures,"rate ratio ( nmbr % cl ) """,measures
1240,placebo group,measures;arms,arms,placebo group,arms
1242,hdl cholesterol ( week nmbr ) a,measures;outcomes,characteristic_name,hdl cholesterol ( week nmbr ) a,characteristic_name
1243,non - hdl cholesterol ( week nmbr ),measures;outcomes,characteristic_name,non - hdl cholesterol ( week nmbr ),characteristic_name
1244,"mmol / l """,measures;outcomes,characteristic_level,"mmol / l """,characteristic_level
1245,lp ( a ) ( week nmbr ),measures;outcomes,measures,lp ( a ) ( week nmbr ),measures
1246,calculated ldl cholesterol ( week nmbr ),measures;outcomes,characteristic_name,calculated ldl cholesterol ( week nmbr ),characteristic_name
1247,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,measures;outcomes,measures,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,measures
1248,ldl particle numbers ( week nmbr ),measures;outcomes,measures,ldl particle numbers ( week nmbr ),measures
1249,ldl particle size ( week nmbr ),measures;outcomes,measures,ldl particle size ( week nmbr ),measures
1250,total cholesterol ( week nmbr ),measures;outcomes,characteristic_name,total cholesterol ( week nmbr ),characteristic_name
1251,mg / dl,measures;outcomes,arms,mg / dl,arms
1252,mmol / l,measures;outcomes,characteristic_level,mmol / l,characteristic_level
1253,triglycerides ( week nmbr ) a,measures;outcomes,measures,triglycerides ( week nmbr ) a,measures
1254,apob ( week nmbr ),measures;outcomes,outcomes,apob ( week nmbr ),outcomes
1255,placebo ( n = nmbr ),measures;arms,arms,placebo ( n = nmbr ),arms
1256,ertugliflozin nmbr mg ( n = nmbr ),measures;arms,arms,ertugliflozin nmbr mg ( n = nmbr ),arms
1257,total ( n = nmbr ),measures;arms,arms,total ( n = nmbr ),arms
1258,"total ( n = nmbr ) """,measures;arms,arms,"total ( n = nmbr ) """,arms
1259,cv death,outcomes;measures,outcomes,cv death,outcomes
1260,months ( log - transformed ),outcomes;measures,arms,months ( log - transformed ),arms
1261,"months ( log - transformed ) """,outcomes;measures,arms,"months ( log - transformed ) """,arms
1262,kccq ( nmbr months ),outcomes;measures,arms,kccq ( nmbr months ),arms
1263,cv death or first hhf,outcomes;measures,outcomes,cv death or first hhf,outcomes
1264,change in nt - probnp at nmbr months ( log - transformed ),outcomes;measures,arms,change in nt - probnp at nmbr months ( log - transformed ),arms
1265,change in sbp ( nmbr months ),outcomes;measures,arms,change in sbp ( nmbr months ),arms
1266,death ( all - cause ),outcomes;measures,outcomes,death ( all - cause ),outcomes
1267,first hhf,outcomes;measures,characteristic_name,first hhf,characteristic_name
1268,p value,outcomes;other,measures,p value,measures
1269,"no stroke ( n = nmbr ) """,outcomes;other,characteristic_level,"no stroke ( n = nmbr ) """,characteristic_level
1270,any stroke ( n = nmbr ),outcomes;other,outcomes,any stroke ( n = nmbr ),outcomes
1271,no stroke ( n = nmbr ),outcomes;other,characteristic_level,no stroke ( n = nmbr ),characteristic_level
1272,p - int,arms;other;p-interaction,characteristic_name,p - int,characteristic_name
1273,ez / simva < % >,arms;other;p-interaction,arms,ez / simva < % >,arms
1274,"p - int """,arms;other;p-interaction,characteristic_name,"p - int """,characteristic_name
1275,hr ( nmbr % ci ),arms;other;p-interaction,measures,hr ( nmbr % ci ),measures
1276,simva ( % ),arms;other;p-interaction,arms,simva ( % ),arms
1277,total patients,arms;other;p-interaction,measures,total patients,measures
1278,"no prior stroke """,characteristic_name;p-interaction,characteristic_level,"no prior stroke """,characteristic_level
1279,prior stroke,characteristic_name;p-interaction,characteristic_level,prior stroke,characteristic_level
1280,p interaction,characteristic_name;p-interaction,characteristic_name,p interaction,characteristic_name
1281,no prior stroke,characteristic_name;p-interaction,characteristic_level,no prior stroke,characteristic_level
1282,simva n = nmbr n ( % ),arms;measures,arms,simva n = nmbr n ( % ),arms
1283,arr ( nmbr % cl ),arms;measures,measures,arr ( nmbr % cl ),measures
1284,"simva n = nmbr n ( % ) """,arms;measures,arms,"simva n = nmbr n ( % ) """,arms
1286,ez / simva n = nmbr n ( % ),arms;measures,arms,ez / simva n = nmbr n ( % ),arms
1288,risk difference,arms;measures,measures,risk difference,measures
1289,pioglitazone,arms;measures,characteristic_name,pioglitazone,characteristic_name
1292,"noncomplex anatomy ( n - nmbr , nmbr )",arms;other,characteristic_level,"noncomplex anatomy ( n - nmbr , nmbr )",characteristic_level
1293,"complex anatomy ( n - nmbr , nmbr ) """,arms;other,characteristic_level,"complex anatomy ( n - nmbr , nmbr ) """,characteristic_level
1294,"complex anatomy ( n - nmbr , nmbr )",arms;other,characteristic_level,"complex anatomy ( n - nmbr , nmbr )",characteristic_level
1297,pioglitazone,arms;measures;p-interaction,characteristic_name,pioglitazone,characteristic_name
1298,"placebo """,arms;measures;p-interaction,arms,"placebo """,arms
1299,int . p *,arms;measures;p-interaction,characteristic_name,int . p *,characteristic_name
1300,low - dose rivaroxaban + aspirin ( n / n ),arms;p-interaction,arms,low - dose rivaroxaban + aspirin ( n / n ),arms
1301,hr ( nmbr % ci ),arms;p-interaction,measures,hr ( nmbr % ci ),measures
1302,"hr ( nmbr % ci ) """,arms;p-interaction,measures,"hr ( nmbr % ci ) """,measures
1303,aspirin alone ( n / n ),arms;p-interaction,arms,aspirin alone ( n / n ),arms
1304,pinteraction,arms;p-interaction,characteristic_name,pinteraction,characteristic_name
1305,hr ( nmbr % ci ),arms;p-interaction;measures,measures,hr ( nmbr % ci ),measures
1306,pinteraction,arms;p-interaction;measures,characteristic_name,pinteraction,characteristic_name
1307,aspirin alone group no of events / total n ( % ),arms;p-interaction;measures,arms,aspirin alone group no of events / total n ( % ),arms
1308,low - dose rivaroxaban + aspirin group,arms;p-interaction;measures,arms,low - dose rivaroxaban + aspirin group,arms
1309,"aspirin alone group no of events / total n ( % ) """,arms;p-interaction;measures,arms,"aspirin alone group no of events / total n ( % ) """,arms
1310,"placebo ,",measures;arms,arms,"placebo ,",arms
1311,etd ( nmbr % ci ),measures;arms,measures,etd ( nmbr % ci ),measures
1312,"etd ( nmbr % ci ) """,measures;arms,measures,"etd ( nmbr % ci ) """,measures
1313,"liraglutide nmbr . nmbr mg ,",measures;arms,arms,"liraglutide nmbr . nmbr mg ,",arms
1314,"placebo ,",arms;measures,arms,"placebo ,",arms
1315,liraglutide nmbr . nmbr mg,arms;measures,arms,liraglutide nmbr . nmbr mg,arms
1316,"etd ( nmbr % ci ) """,arms;measures,measures,"etd ( nmbr % ci ) """,measures
1317,"liraglutide nmbr . nmbr mg ,",arms;measures,arms,"liraglutide nmbr . nmbr mg ,",arms
1318,etd ( nmbr % ci ),arms;measures,measures,etd ( nmbr % ci ),measures
1319,hr ( nmbr % ci ),arms;measures,measures,hr ( nmbr % ci ),measures
1320,pbo / simva - nmbryr km rale ( % ),arms;measures,arms,pbo / simva - nmbryr km rale ( % ),arms
1321,"eze / simva - nmbryr km rale ( % ) """,arms;measures,arms,"eze / simva - nmbryr km rale ( % ) """,arms
1322,eze / simva - nmbryr km rale ( % ),arms;measures,arms,eze / simva - nmbryr km rale ( % ),arms
1323,"pin / """,arms;p-interaction;other,characteristic_name,"pin / """,characteristic_name
1324,ezetimibe / simvastatin,arms;p-interaction;other,arms,ezetimibe / simvastatin,arms
1325,pin /,arms;p-interaction;other,characteristic_name,pin /,characteristic_name
1326,p value *,arms;p-interaction;other,measures,p value *,measures
1327,placebo / simvastatin,arms;p-interaction;other,arms,placebo / simvastatin,arms
1328,"pin / """,arms;measures;p-interaction,characteristic_name,"pin / """,characteristic_name
1329,ezetimibe / simvastatin,arms;measures;p-interaction,arms,ezetimibe / simvastatin,arms
1330,pin /,arms;measures;p-interaction,characteristic_name,pin /,characteristic_name
1331,p value *,arms;measures;p-interaction,measures,p value *,measures
1332,placebo / simvastatin,arms;measures;p-interaction,arms,placebo / simvastatin,arms
1334,diabetes absent nmbr ( nmbr . nmbr ),arms;measures,characteristic_level,diabetes absent nmbr ( nmbr . nmbr ),characteristic_level
1335,diabetes present nmbr ( nmbr . nmbr ),arms;measures,characteristic_level,diabetes present nmbr ( nmbr . nmbr ),characteristic_level
1336,"diabetes present nmbr ( nmbr . nmbr ) """,arms;measures,characteristic_level,"diabetes present nmbr ( nmbr . nmbr ) """,characteristic_level
1340,"placebo / simvastatin """,arms;measures;p-interaction,arms,"placebo / simvastatin """,arms
1343,"mvd ( n - nmbr , nmbr )",arms;other,characteristic_level,"mvd ( n - nmbr , nmbr )",characteristic_level
1344,"no mvd ( n - nmbr , nmbr ) """,arms;other,characteristic_level,"no mvd ( n - nmbr , nmbr ) """,characteristic_level
1345,"no mvd ( n - nmbr , nmbr )",arms;other,characteristic_level,"no mvd ( n - nmbr , nmbr )",characteristic_level
1346,"ef > nmbr % hfpef ( n = nmbr , nmbr % )",arms;measures,characteristic_level,"ef > nmbr % hfpef ( n = nmbr , nmbr % )",characteristic_level
1347,"p - value for trend * """,arms;measures,measures,"p - value for trend * """,measures
1348,"ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )",arms;measures,characteristic_level,"ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )",characteristic_level
1349,"ef < nmbr % hfref ( n = nmbr , nmbr % )",arms;measures,characteristic_level,"ef < nmbr % hfref ( n = nmbr , nmbr % )",characteristic_level
1350,p - value for trend *,arms;measures,measures,p - value for trend *,measures
1351,ef > nmbr %,characteristic_name;p-interaction,characteristic_level,ef > nmbr %,characteristic_level
1352,p - interaction,characteristic_name;p-interaction,characteristic_name,p - interaction,characteristic_name
1353,"ef > nmbr % """,characteristic_name;p-interaction,characteristic_level,"ef > nmbr % """,characteristic_level
1354,ef < nmbr %,characteristic_name;p-interaction,characteristic_level,ef < nmbr %,characteristic_level
1355,ef nmbr - nmbr %,characteristic_name;p-interaction,characteristic_level,ef nmbr - nmbr %,characteristic_level
